<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Xenobiot</journal-id><journal-id journal-id-type="iso-abbrev">J Xenobiot</journal-id><journal-id journal-id-type="publisher-id">jox</journal-id><journal-title-group><journal-title>Journal of Xenobiotics</journal-title></journal-title-group><issn pub-type="ppub">2039-4705</issn><issn pub-type="epub">2039-4713</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8708150</article-id><article-id pub-id-type="pmid">34940513</article-id><article-id pub-id-type="doi">10.3390/jox11040013</article-id><article-id pub-id-type="publisher-id">jox-11-00013</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Review on Multiple Facets of Drug Resistance: A Rising Challenge in the 21st Century</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5115-2045</contrib-id><name><surname>Saha</surname><given-names>Mousumi</given-names></name><xref rid="af1-jox-11-00013" ref-type="aff">1</xref><xref rid="c1-jox-11-00013" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3692-0381</contrib-id><name><surname>Sarkar</surname><given-names>Agniswar</given-names></name><xref rid="af2-jox-11-00013" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Cheong</surname><given-names>Yuen-Ki</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jox-11-00013"><label>1</label>Department of Microbiology, Ballygunge Science College, University of Calcutta, 35, Ballygunge Circular Road, Kolkata 700019, India</aff><aff id="af2-jox-11-00013"><label>2</label>Virus Unit [NICED-ICMR], GB4-1st Floor, ID and BG Hospital, 57, S. C. Banerjee Road, Beliaghata, Kolkata 700010, India; <email>ognish@gmail.com</email></aff><author-notes><corresp id="c1-jox-11-00013"><label>*</label>Correspondence: <email>mou.cute@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>12</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2021</year></pub-date><volume>11</volume><issue>4</issue><fpage>197</fpage><lpage>214</lpage><history><date date-type="received"><day>23</day><month>11</month><year>2021</year></date><date date-type="accepted"><day>09</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>With the advancements of science, antibiotics have emerged as an amazing gift to the human and animal healthcare sectors for the treatment of bacterial infections and other diseases. However, the evolution of new bacterial strains, along with excessive use and reckless consumption of antibiotics have led to the unfolding of antibiotic resistances to an excessive level. Multidrug resistance is a potential threat worldwide, and is escalating at an extremely high rate. Information related to drug resistance, and its regulation and control are still very little. To interpret the onset of antibiotic resistances, investigation on molecular analysis of resistance genes, their distribution and mechanisms are urgently required. Fine-tuned research and resistance profile regarding ESKAPE pathogen is also necessary along with other multidrug resistant bacteria. In the present scenario, the interaction of bacterial infections with SARS-CoV-2 is also crucial. Tracking and in-silico analysis of various resistance mechanisms or gene/s are crucial for overcoming the problem, and thus, the maintenance of relevant databases and wise use of antibiotics should be promoted. Creating awareness of this critical situation among individuals at every level is important to strengthen the fight against this fast-growing calamity. The review aimed to provide detailed information on antibiotic resistance, its regulatory molecular mechanisms responsible for the resistance, and other relevant information. In this article, we tried to focus on the correlation between antimicrobial resistance and the COVID-19 pandemic. This study will help in developing new interventions, potential approaches, and strategies to handle the complexity of antibiotic resistance and prevent the incidences of life-threatening infections.</p></abstract><kwd-group><kwd>multidrug resistance</kwd><kwd>infection control strategy</kwd><kwd>ESKAPE</kwd><kwd>COVID-19</kwd><kwd>molecular mechanism</kwd><kwd>in-silico analysis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-jox-11-00013"><title>1. Introduction</title><p>Recently, antibiotic resistance in various bacteria has emerged as a global threat to the treatment options for bacterial infections, and a subject of current research [<xref rid="B1-jox-11-00013" ref-type="bibr">1</xref>,<xref rid="B2-jox-11-00013" ref-type="bibr">2</xref>]. Antibiotic resistance is not only a major complication: antimicrobial resistance (AMR) is also one of the top ten global public health concerns flourishing all over the world. Antibiotics, antiviral, antifungal, and antiparasitics are commonly known as antimicrobials. The scenario regarding the adverse effects of resistance is much bigger than its imagination. Antiviral drug resistance is also increasing at an alarming rate, and has become a concern for immunocompromised patients. Antiretroviral drugs are one of the best examples of this problem. Drug resistance to malaria parasites and fungal infections are increasing and infuriating the treatment situation. Dated back in May 2015, the WHO has developed Global Action Plan on AMR with five objectives to fight steps against AMR [<xref rid="B3-jox-11-00013" ref-type="bibr">3</xref>,<xref rid="B4-jox-11-00013" ref-type="bibr">4</xref>]. On 11 March 2020, WHO [<xref rid="B5-jox-11-00013" ref-type="bibr">5</xref>] declared that the world was under the calamity of a Coronavirus disease (COVID-19) pandemic caused by novel Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) [<xref rid="B6-jox-11-00013" ref-type="bibr">6</xref>,<xref rid="B7-jox-11-00013" ref-type="bibr">7</xref>,<xref rid="B8-jox-11-00013" ref-type="bibr">8</xref>]. Interestingly, in November of the same year, World Antimicrobial Awareness Week was arranged, and a slogan of &#x02018;Antimicrobials Handle with Care&#x02019; was highlighted to win the battle of antibiotic resistance [<xref rid="B9-jox-11-00013" ref-type="bibr">9</xref>], as, in the present situation, antibiotic misuse or excessive use can be related to COVID-19 treatment [<xref rid="B10-jox-11-00013" ref-type="bibr">10</xref>]. Few environmental bacteria are also believed to acquire antibiotic resistance determinants, which could be due to co-existence/evolution or horizontal gene transfer (HGT) [<xref rid="B11-jox-11-00013" ref-type="bibr">11</xref>,<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>]. Thus, all of these factors, along with the excessive use of antibiotics, are responsible for the emergence of resistance in isolates [<xref rid="B13-jox-11-00013" ref-type="bibr">13</xref>]. Threats caused by both gram-negative and gram-positive resistant bacterial strains have compelled scientists to explore new classes of antibiotics and novel approaches to tackle the problem of resistance [<xref rid="B14-jox-11-00013" ref-type="bibr">14</xref>,<xref rid="B15-jox-11-00013" ref-type="bibr">15</xref>].</p><p>AMR is not only hindering the health sector but is also an economic burden for developed, as well as for developing countries [<xref rid="B16-jox-11-00013" ref-type="bibr">16</xref>]. Several treatment procedures are at risk without antibiotics, such as organ transplantation, chemotherapy, and surgeries. However, not only antibiotics are necessary for treating infectious diseases and small injuries. However, without common antibiotics, more expensive medicine, prolonging the duration of treatment and longer hospital exposure, will enhance the cost of treatment with the requirement of intensive care, and finally lead to life-threatening damage.</p><p>In this review, we attempted to embellish the key features of antibiotic resistance (AMR), its consequences, mechanisms, regulation, association, and control strategies. Raising awareness and educating people are the most important steps for controlling antibiotic resistance. Irradiation of AMR is a goal of sustainable development, and together we must achieve this. The present review focuses on the surveillance of the origin of antibiotic resistance, genetic and functional characterization of resistance factors, and therapeutic options. Through this review, we also attempted to draw attention to the irrational use of antibiotics and their negative consequences. The review will help researchers/scientists in creating preventive tools and diagnostic pathways. Here, we tried to explore the multiple interaction impact of AMR with COVID-19 by understanding the usage of antimicrobial agents, the role of the healthcare system, and preventive measures.</p></sec><sec id="sec2-jox-11-00013"><title>2. Brief History and Background</title><p>The discovery of penicillin in 1928 by Alexander Fleming was a pillar for the foundation of the modern era of treatment for bacterial infections [<xref rid="B17-jox-11-00013" ref-type="bibr">17</xref>]. The origin of antibiotics dates back a few decades, and since then they have been playing an important role in impeding the growth of pathogenic microbes. Antibiotic resistance emerged in the 1960s, when various enteric and other gram-negative bacteria developed resistance toward highly used drugs. Overall, three major elements of AMR development are emergence, transmission, and level of infection. For example, <italic toggle="yes">Neisseria gonorrhoeae (N.</italic>
<italic toggle="yes">gonorrhoeae</italic>) developed resistance to ampicillin, and <italic toggle="yes">Haemophilus</italic> developed resistance to ampicillin, tetracycline, and chloramphenicol [<xref rid="B18-jox-11-00013" ref-type="bibr">18</xref>,<xref rid="B19-jox-11-00013" ref-type="bibr">19</xref>]. Similarly, sulfonamide resistance originated in the 1940s, and soon after the origin of sulfonamide resistance, pharmaceutical companies and researchers had to face another hurdle when aminoglycoside-resistant <italic toggle="yes">S. aureus</italic> came into existence. Afterwards, with the development of new antibiotics, such as methicillin, vancomycin, and fluoroquinolones, the emergence of resistance to these antibiotics also developed gradually; methicillin-resistant <italic toggle="yes">S. aureus</italic> (MRSA) strains are among the rapidly propagating bacterial strains [<xref rid="B20-jox-11-00013" ref-type="bibr">20</xref>].</p><p>With the advancement of genome biology, scientists are becoming aware of the genome sequence of various bacteria, and approximately 20,000 antibiotic resistance genes have been identified to date. However, the lack of data regarding molecular, genetic, and biochemical mechanisms is the major hindrance in resolving this vital issue [<xref rid="B21-jox-11-00013" ref-type="bibr">21</xref>]. Shortage of funds, as well as development of new drugs, are also the key concerns. The incorporation of bioinformatics tools and techniques can help to recover this hurdle with the available information of genome sequence [<xref rid="B22-jox-11-00013" ref-type="bibr">22</xref>]. Disposal of antibiotics or related items without adhering to rules and regulations, hospital-acquired antibiotic resistances, improper hygiene and sanitation systems, excessive utilization of antibiotics in livestock management (poultry, aquatic, etc.), and international travel are a few factors for the outbreak of antibiotic resistance in the human and animal community [<xref rid="B1-jox-11-00013" ref-type="bibr">1</xref>]. All of these factors contribute to the escalation of resistance in the environmental niche, which is also a serious global concern [<xref rid="B11-jox-11-00013" ref-type="bibr">11</xref>]. Examples of some infectious diseases are pneumonia, tuberculosis, gonorrhea, salmonellosis, foodborne disease, blood poisoning, etc., which are treated with different types of antibiotics [<xref rid="B1-jox-11-00013" ref-type="bibr">1</xref>,<xref rid="B23-jox-11-00013" ref-type="bibr">23</xref>]. However, with increased resistance, common antibiotics are becoming less functional for the treatment of various diseases. These problems are associated with prolonged treatment, enhanced medical cost, and, in some cases, finally result in mortality. Therefore, new drugs and different treatment options are required [<xref rid="B9-jox-11-00013" ref-type="bibr">9</xref>,<xref rid="B24-jox-11-00013" ref-type="bibr">24</xref>].</p></sec><sec id="sec3-jox-11-00013"><title>3. Features of Different Resistant Bacteria</title><p>The World Health Organization (WHO) and Center for Disease Control and Prevention (CDC) declared the rapidly growing antibiotic resistance as one of the major global concerns [<xref rid="B25-jox-11-00013" ref-type="bibr">25</xref>]. As per the CDC report (13 November 2019; <uri xlink:href="www.cdc.gov/drugresistance/pdf/threatsreport/2019">www.cdc.gov/drugresistance/pdf/threatsreport/2019</uri>), antibiotic resistance threats were categorized under four sections, with the name of the strains as described here: (a) Urgent Threats (Carbapenem-resistant <italic toggle="yes">Acinetobacter</italic>; <italic toggle="yes">Candida auris</italic>; <italic toggle="yes">Clostridioides difficile</italic>; Carbapenem-resistant Enterobacterales; Drug-resistant <italic toggle="yes">Neisseria gonorrhoeae),</italic> (b) Serious Threats (Drug-resistant <italic toggle="yes">Campylobacter;</italic> Drug-resistant <italic toggle="yes">Candida</italic>; ESBL-producing Enterobacterales; Vancomycin-resistant <italic toggle="yes">Enterococci</italic> (VRE); Multidrug-resistant <italic toggle="yes">Pseudomonas aeruginosa</italic>; Drug-resistant nontyphoidal <italic toggle="yes">Salmonella</italic>; Drug-resistant <italic toggle="yes">Salmonella</italic> serotype Typhi; Drug-resistant <italic toggle="yes">Shigella</italic>; Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA); Drug-resistant <italic toggle="yes">Streptococcus pneumoniae</italic>; Drug-resistant Tuberculosis), Concerning Threats (Erythromycin-Resistant Group A <italic toggle="yes">Streptococcus</italic>; Clindamycin-resistant Group B <italic toggle="yes">Streptococcus</italic>), and Watch List (Azole-resistant <italic toggle="yes">Aspergillus fumigatus</italic>; Drug-resistant <italic toggle="yes">Mycoplasma genitalium</italic>; Drug-resistant <italic toggle="yes">Bordetella pertussis</italic>).</p><p>Based on the extent of resistance towards different drugs, AMR has been further classified into multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan drug-resistant (PDR) [<xref rid="B26-jox-11-00013" ref-type="bibr">26</xref>,<xref rid="B27-jox-11-00013" ref-type="bibr">27</xref>]. Recently, difficult-to-treat resistance (DTR) and modified DTR have also been categorized [<xref rid="B25-jox-11-00013" ref-type="bibr">25</xref>,<xref rid="B28-jox-11-00013" ref-type="bibr">28</xref>]. &#x0201c;MDR was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories as per guidelines. XDR was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories listed and PDR was defined as non-susceptibility to all agents in all antimicrobial categories&#x0201d; according to the European Centre for Disease Control (ECDC) and the CDC [<xref rid="B28-jox-11-00013" ref-type="bibr">28</xref>]. <italic toggle="yes">Staphylococcus aureus (S. aureus</italic>), <italic toggle="yes">Enterococcus</italic> spp., <italic toggle="yes">Enterobacteriaceae</italic>, <italic toggle="yes">Pseudomonas aeruginosa (P. aeruginosa</italic>), and <italic toggle="yes">Acinetobacter</italic> spp. are just a few examples of multiple drug-resistant bacteria [<xref rid="B27-jox-11-00013" ref-type="bibr">27</xref>]. MDR is an obstacle for developing countries due to inadequate health systems, and limitations of funds and resources. MDR gram-negative bacteria such as extended-spectrum &#x003b2;-lactamase (ESBL)-producing <italic toggle="yes">Enterobacteriaceae</italic> and carbapenem-resistant <italic toggle="yes">Enterobacteriaceae</italic> (CRE) have become a health issue for neonates. Few specific treatment options and monitoring initiatives have been taken into account by WHO under NeoAMR Project [<xref rid="B29-jox-11-00013" ref-type="bibr">29</xref>]. Bacteria possess unique self-defence mechanisms against their antibiotics [<xref rid="B30-jox-11-00013" ref-type="bibr">30</xref>]. </p><p>To understand the conception and consequences of MDR, the origin, source, mobilization, and molecular factors of these determinants should be thoroughly studied. MDR is becoming increasingly common among various pathogenic and non-pathogenic strains, and is mostly associated with the acquisition of genes and/or modification in the antibiotic target genes [<xref rid="B31-jox-11-00013" ref-type="bibr">31</xref>]. The regulators of MDR in bacteria are considered cardinal to the survival and adaptability of the bacterial community to unfavorable and extreme conditions, including the presence of antibiotics or other drugs. Antibiotic resistance or MDR is associated with the acquisition of genes and/or modification in the antibiotic target genes [<xref rid="B32-jox-11-00013" ref-type="bibr">32</xref>]. The accessibility of a large amount of sequencing information for bacterial genomes along with the functional data of various mobile genetic elements that have amassed over for nearly four decades has permitted the research community to broadly review the epidemiological aspects of MDR hereditary determinants of pathogenic and natural microbes [<xref rid="B33-jox-11-00013" ref-type="bibr">33</xref>].</p></sec><sec id="sec4-jox-11-00013"><title>4. Origin and Development of Resistance</title><p>Essentially, antibiotic resistance is developed by bacteria via their natural selection process or through their survival strategy in harsh environmental conditions, but irrational use has accelerated the resistance. Resistant bacteria then invade the human or animal and develop various infectious diseases [<xref rid="B34-jox-11-00013" ref-type="bibr">34</xref>]. Molecular studies on determining the origin strongly suggest that microorganisms are proficient in genetic recombination and may exchange antibiotic resistance-related gene cassettes. Comparative genomic and transcriptomic studies of the strains have helped researchers to assess their phylogenetic orientation and gene expression. However, the functional diversity and similarity between resistant strains should be explored to improve the modern healthcare system and reduce the incidence of community-acquired infections [<xref rid="B21-jox-11-00013" ref-type="bibr">21</xref>,<xref rid="B35-jox-11-00013" ref-type="bibr">35</xref>].</p><p>Several gram-negative bacteria are responsible for causing community-acquired infections and are thus considered hazardous, posing a risk to the modern healthcare system [<xref rid="B1-jox-11-00013" ref-type="bibr">1</xref>]. Integration of antibiotic resistance genes or MGEs is responsible for antibiotic resistance into bacterial chromosomes [<xref rid="B36-jox-11-00013" ref-type="bibr">36</xref>]. However, information regarding the mechanism and expression of the regulators of antibiotic resistance is scant. The consumption of antibiotics by animals in their food leads to some degree of antibiotic resistance even in human beings [<xref rid="B1-jox-11-00013" ref-type="bibr">1</xref>]. The utilization of animal models can help in assessing the effects of antimicrobial resistance and pathological mechanisms. With the advancement of science, various semi-synthetic, synthetic, and broad-spectrum antibiotics have been developed with specificity toward the causative agent and not the host. However, the outrageous use of antibiotics in the human, as well as animal healthcare systems, is one of the major factors for the emergence of MDR [<xref rid="B26-jox-11-00013" ref-type="bibr">26</xref>]. Lack of treatment guidelines, and over-prescription of antibiotics by health workers and veterinarians also contribute to in rising in antibiotic resistance [<xref rid="B1-jox-11-00013" ref-type="bibr">1</xref>].</p><p>Resistance toward a specific antibiotic drug may originate at any time point, and the reasons could be natural selection pressure or non-judicial use of antibiotics without adequate knowledge. The food chain may be another reason for the origin of drug resistance [<xref rid="B37-jox-11-00013" ref-type="bibr">37</xref>]. Typically, similar classes or types of antibiotics are used in agriculture, human treatment, as well as in cattle or dairy farms, that lead to the spread of antibiotic resistance followed by the transmission of resistance traits. Excessive use of antimicrobial agents in human, animal, and agricultural production leads to environmental contamination, especially water bodies, which need further consideration [<xref rid="B1-jox-11-00013" ref-type="bibr">1</xref>]. Colistin addition to animal feed needs to be restricted or stop to avoid antibiotic resistance and contamination [<xref rid="B38-jox-11-00013" ref-type="bibr">38</xref>]. The use of huge biocide-based items and their disposal into soil or water bodies may have some negative impact on the environment, and may elevate the rate of resistance traits among micro-organisms [<xref rid="B39-jox-11-00013" ref-type="bibr">39</xref>]. All of these reasons contribute to the origin, emergence, and spread of resistance from the environment, waste disposal and community (<xref rid="jox-11-00013-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec5-jox-11-00013"><title>5. Characterization of Antibiotic Resistance Factors</title><p>Antibiotic resistance is vital for the survival of bacteria, and they can acquire self-defence against antibiotics. Thus, antibiotic resistances are carried via natural selection as well as directly by the transfer of genes or genetic determinants. Excessive use of antibiotics or an incomplete course of antibiotics leads to increased antibiotic resistance (which can be strongly correlated with its consumption). Infectious or pathogenic bacteria remain unaffected or partially affected, and this may increase the chances of relapse of the infection or the disease. In these cases, similar or sometimes different broad-spectrum antibiotics are used, and thus bacteria may acquire MDR through different mechanisms. However, all these factors lead to the origin and occurrence of antibiotic resistance among clinical as well as environmental strains [<xref rid="B8-jox-11-00013" ref-type="bibr">8</xref>,<xref rid="B24-jox-11-00013" ref-type="bibr">24</xref>].</p><p>Strains of environmental origin may carry various mobile genetic elements (MGE), including antibiotic resistance genes [<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>,<xref rid="B13-jox-11-00013" ref-type="bibr">13</xref>]. The genetic exchange occurs extensively in the environment, as well as under in vivo conditions, and other opportunistic pathogens may inherit or uptake resistant genes. MGE in gram-negative and gram-positive bacteria are assumed to play a vital role in conferring adaptation in the bacterial community, permitting them to rapidly adapt to unfavorable conditions, including the presence of antibiotics [<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>,<xref rid="B13-jox-11-00013" ref-type="bibr">13</xref>]. Integrative and conjugative plasmids are effective means of scattering the MDR traits in a broad range of pathogenic <italic toggle="yes">Enterobacteriaceae</italic> strains. Studies have reported a vital role of versatile hereditary components, such as conjugative plasmids and integrative conjugative elements (ICEs) in the spread of MDR [<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>,<xref rid="B40-jox-11-00013" ref-type="bibr">40</xref>,<xref rid="B41-jox-11-00013" ref-type="bibr">41</xref>]. Therefore, extensive molecular characterization of these genes must be developed for novel therapeutic strategies.</p><p>Broadly, antibiotic resistance can be classified into four types: (1) natural/intrinsic resistance, and (2) acquired resistance. <xref rid="jox-11-00013-t001" ref-type="table">Table 1</xref> summarizes a few mechanisms of resistance to different target drugs having different modes of action.</p><sec id="sec5dot1-jox-11-00013"><title>5.1. Natural/Intrinsic Resistance</title><p>Intrinsic resistance can be defined as the ability of a bacterium to resist the effect of an antibiotic due to its inherent properties. An excellent example of an intrinsic resistance mechanism is the absence of a susceptible target site for a particular antibiotic in <italic toggle="yes">Pseudomonas</italic>. Triclosan, a broad-spectrum biocide especially against gram-positive bacteria and several gram-negative bacteria, is incapable of preventing the growth of <italic toggle="yes">Pseudomonas</italic>. Initially, the resistance was supposed to be due to active efflux, but later on, the presence of <italic toggle="yes">fabI</italic> (insensitive allele) which encodes an extra enoyl-acyl carrier protein reductase enzyme, a target site for triclosan, was reported [<xref rid="B46-jox-11-00013" ref-type="bibr">46</xref>]. Similarly, lipopeptide daptomycin, approved in 2003 for clinical practice, is an active drug against gram-positive bacteria (36). However, it is ineffective against gram-negative bacteria. The cytoplasmic membrane of gram-negative bacteria contains the lesser proportion of anionic phospholipids than gram-positive bacteria. Thus, the efficacy of Ca<sup>2+</sup> mediated daptomycin insertion into the cytoplasmic membrane is decreased [<xref rid="B47-jox-11-00013" ref-type="bibr">47</xref>]. Additionally, some antibacterial compounds that are unable to cross the outer membrane are considered as a means of intrinsic resistance. In gram-positive bacteria, vancomycin inhibits peptidoglycan crosslinking by targeting D-Ala-D-Ala peptides, whereas, in the case of gram-negative bacteria, vancomycin cannot pass through the outer membrane. The synthesis of &#x003b2;-lactamases (e.g., extended-spectrum &#x003b2;-lactamases [ESBLs] enzymes, carbapenemases, and metallo-&#x003b2;-lactamases) has reportedly increased the rate of acquired MDR infections, and it has particularly led to third-generation cephalosporin and carbapenem resistance. Notably, various genes associated with intrinsic resistance to different classes of antibiotics such as lactams, aminoglycosides, and fluoroquinolones in <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">S. aureus</italic>, and <italic toggle="yes">Escherichia coli</italic> (<italic toggle="yes">E. coli</italic>) have been identified through high-throughput tools of high-density genome mutant libraries [<xref rid="B48-jox-11-00013" ref-type="bibr">48</xref>]. Genes responsible for drug-resistant <italic toggle="yes">Salmonella</italic> and <italic toggle="yes">E. coli</italic> include <italic toggle="yes">AmpC, bla-TEM-1, bla-CTX- M-15, VIM-1, NDM-1, floR, tetG</italic>, and the <italic toggle="yes">mcr-1</italic> gene that encodes colistin drug resistance [<xref rid="B49-jox-11-00013" ref-type="bibr">49</xref>]. As an example, the inactivation of redundant <italic toggle="yes">E. coli</italic> genes enabled the identification of putative targets, such as FabI, SapC, RecQ, TrxA (thioredoxin), TrxB (thioredoxin reductase), DacA, and D-Ala-D-Ala carboxypeptidase, for susceptibility phenotyping. Inhibition of these genes may significantly stimulate the activity of drugs such as triclosan, rifampicin, aminoglycosides, nitrofurantoin, and some &#x003b2;-lactams. Bacteria may acquire antibiotic resistance through various other mechanisms, such as antibiotic efflux or poor drug penetration resulting in the reduction of the intracellular concentration of antibiotic, modification of the antibiotic target site due to posttranslational target modification or genetic mutation of the target, and inactivation of antibiotics through modification or hydrolysis [<xref rid="B32-jox-11-00013" ref-type="bibr">32</xref>,<xref rid="B50-jox-11-00013" ref-type="bibr">50</xref>]. Plasmid coding colistin-resistant (mcr-1 dependent) <italic toggle="yes">E. coli</italic> was first isolated from raw meat, animals, and humans in China [<xref rid="B51-jox-11-00013" ref-type="bibr">51</xref>]; Mcr-1 harboring <italic toggle="yes">E. coli</italic> was also reported in migratory birds and human clinical isolates in Pakistan and MDR (ESBLs, quinolones). <italic toggle="yes">E. coli</italic> was reported from poultry farms, wild birds, pigeons, dogs, and humans [<xref rid="B52-jox-11-00013" ref-type="bibr">52</xref>], as a few examples. <italic toggle="yes">N. gonorrhoeae</italic> has developed resistance to sulphonamides, penicillins, tetracyclines, macrolides, fluoroquinolones, and early generation cephalosporins [<xref rid="B53-jox-11-00013" ref-type="bibr">53</xref>]. Apart from rifampicin-resistant <italic toggle="yes">Mycobacterium tuberculosis</italic> (<italic toggle="yes">M. tuberculosis</italic>) strains also show multi-drug resistance and pose a major risk factor for the treatment of tuberculosis [<xref rid="B54-jox-11-00013" ref-type="bibr">54</xref>].</p></sec><sec id="sec5dot2-jox-11-00013"><title>5.2. Acquired Resistance</title><p>Acquired resistance is the most important trait, and its mechanism can be further subdivided into the following types: (1) decrease uptake of the drug due to reduction in the internal or external membrane permeability or changes in the cytoplasmic membrane composition; (2) enzymatic inactivation or degradation of antibiotics; (3) active efflux pump system; (4) resistance associated with alteration of the target or change in the structure of the target, and; (5) in some cases, the use of alternative metabolic pathways serves as the resistance mechanism [<xref rid="B22-jox-11-00013" ref-type="bibr">22</xref>]. The gene or the genetic elements responsible for acquired resistance may be chromosomal or extrachromosomal. Antibiotic resistance can occur via various mechanisms linked with virulence factors, outer membrane proteins cell envelope factors specific enzymes, quorum sensing, and biofilm formation and protein secretory systems [<xref rid="B22-jox-11-00013" ref-type="bibr">22</xref>]. Studies have indicated that bacteria are prone to undergo genetic recombination, and thus exchange various virulent and antibiotic resistance-related gene cassettes. Comparative genetic and transcriptomic studies of resistant strains will reveal their phylogenetic orientation and gene expression that can help scientists to discover the resistance determinants in different enteric pathogens and environmental reservoirs of genetic elements. HGT facilitates the transmission of both resistance and virulence factors between bacterial genera or species [<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>]. Features such as MGEs and biofilms help bacteria survive and overcome the antibacterial activity of therapeutics [<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>].</p><p>The genomic island carries various gene clusters responsible for pathogenicity and other functions of the enteric bacteria. The ubiquitous mechanisms of DNA exchange and a high rate of spontaneous mutation in bacteria are the major drivers of MDR. Biofilm is one of the common features of various bacterial strains that aid their survival under stringent conditions. These biofilms restrict the antibiotic from penetrating bacterial cells, and thus protect bacteria from the action of antibiotics, and facilitate the mechanism of resistance [<xref rid="B50-jox-11-00013" ref-type="bibr">50</xref>,<xref rid="B55-jox-11-00013" ref-type="bibr">55</xref>]. Sewage and wastewater treatment plants, hospital effluents, aquaculture, agriculture, and slaughterhouse wastes are the hotspots of genetic exchange [<xref rid="B56-jox-11-00013" ref-type="bibr">56</xref>]. Few external factors are also equally responsible for the enhanced antibiotic resistance, such as improper sanitation methods, unhygienic hospital settings, improper diagnostic, and therapeutic standards. Hospital-acquired community infection is one of the major concerns throughout the world. Hospital-acquired pathogens and co-infections have increased enormously. The hospital environment and the resistance gene reservoirs in the hospital facilitate the emergence and transmission of new modes of antibiotic resistance. Few bacteria harbor various resistance mechanisms (either intrinsic or acquired) that create those strains MDR [<xref rid="B57-jox-11-00013" ref-type="bibr">57</xref>]. Recombination events or HGT facilitate the transfer of genes from resistant strains to susceptible bacterial cells; genetic elements such as transposons, more precisely integron, are responsible for antibiotic resistance [<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>]. Some mechanisms are explained below, and <xref rid="jox-11-00013-f002" ref-type="fig">Figure 2</xref> schematically represents several mechanisms of antibiotic resistances such as increased drug efflux, decreased drug uptake, and drug or target modification/destruction.</p><sec id="sec5dot2dot1-jox-11-00013"><title>5.2.1. Antibiotic Modification or Degradation</title><p>Modification or degradation of antibiotics is one of the most common and important mechanisms of acquired resistance [<xref rid="B22-jox-11-00013" ref-type="bibr">22</xref>]. Bacteria contain genes or gene clusters that encode diverse antibiotic-modifying enzymes. These enzymes are effective against various classes of antibiotics such as aminoglycoside, chloramphenicol, and &#x003b2;-lactam [<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>]. Some of these enzymes are present in pathogenic strains, whereas other enzymes are present in both pathogenic and non-pathogenic strains. Enzymes can physically modify antibiotics, and they can actively decrease the concentration of drugs in the local environment. Therefore, it is a unique challenge to researchers and clinicians considering new approaches to anti-infective therapy [<xref rid="B14-jox-11-00013" ref-type="bibr">14</xref>,<xref rid="B36-jox-11-00013" ref-type="bibr">36</xref>].</p></sec><sec id="sec5dot2dot2-jox-11-00013"><title>5.2.2. Antibiotic Efflux</title><p>Resistance mechanisms of various pathogens mainly involve permeability barriers for the active efflux of drug molecules [<xref rid="B36-jox-11-00013" ref-type="bibr">36</xref>]. Analysis of these mechanisms may be suitable targets for designing novel drugs. The synergistic action of reduced drug uptake and efflux is involved within the multiplicative action of the outer membrane permeability barrier, and it leads to the acquisition of high-level intrinsic and/or acquired resistance in many clinically important bacteria [<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>]. Ongoing trials targeted toward understanding the physical structures, function, and regulation of efflux systems will facilitate the exploitation of efflux pumps as new drug targets [<xref rid="B22-jox-11-00013" ref-type="bibr">22</xref>,<xref rid="B50-jox-11-00013" ref-type="bibr">50</xref>].</p></sec><sec id="sec5dot2dot3-jox-11-00013"><title>5.2.3. Use of an Alternative Metabolic Pathway</title><p>Bacteria may also acquire antibiotic resistance by using alternate metabolic pathways [<xref rid="B22-jox-11-00013" ref-type="bibr">22</xref>]. A similar resistance mechanism was reported in small colony variants (SCVs) of <italic toggle="yes">S. aureus</italic>, the mechanism involved the activation of an alternative transcriptional program, leading to increased ATP production while retaining antibiotic resistance in SCVs. The growth rate of drug-resistant SCVs was also found to be high [<xref rid="B58-jox-11-00013" ref-type="bibr">58</xref>]. Similarly, bacteria can acquire the property of utilizing folate present in the environment rather than synthesizing folate [<xref rid="B59-jox-11-00013" ref-type="bibr">59</xref>].</p></sec><sec id="sec5dot2dot4-jox-11-00013"><title>5.2.4. Reduction of the Inner and Outer Membrane Permeability</title><p>Porin mutations in resistant strains result in changes in membrane permeability and decrease drug uptake into the cell [<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>]. For example, in <italic toggle="yes">P. aeruginosa</italic> strains, OprD (specific porin) can cause mutation for carbapenem resistance. Moreover, reduction in permeability of the outer membrane may play an important role in conferring resistance to quinolones and aminoglycosides [<xref rid="B60-jox-11-00013" ref-type="bibr">60</xref>,<xref rid="B61-jox-11-00013" ref-type="bibr">61</xref>]. Alterations of porins could be achieved by three general processes: (1) a shift in the type of porins expressed, (2) a change in the level of porin expression, and (3) impairment of the porin function. Importantly, changes in permeability through any of those mechanisms frequently end in low-level resistance and are often related to other mechanisms of resistance, such as increased expression of efflux pumps [<xref rid="B62-jox-11-00013" ref-type="bibr">62</xref>].</p></sec></sec></sec><sec id="sec6-jox-11-00013"><title>6. Antibiotic Sequestration</title><p>The function of drug-binding proteins that inhibits the attachment of antibiotics with their target is defined as antibiotic sequestration. An example is the primary mechanism of resistance involved in producers of the bleomycin antibiotic family, where metal-bound or metal-free antibiotics are sequestered [<xref rid="B30-jox-11-00013" ref-type="bibr">30</xref>] by binding proteins, namely TlmA (in <italic toggle="yes">Streptoalloteichus</italic>
<italic toggle="yes">hindustanus</italic> ATCC 31158) [<xref rid="B63-jox-11-00013" ref-type="bibr">63</xref>], BlmA (in <italic toggle="yes">Streptomyces verticillus</italic>) [<xref rid="B64-jox-11-00013" ref-type="bibr">64</xref>] and ZbmA (in <italic toggle="yes">Streptomyces</italic>
<italic toggle="yes">flavoviridis</italic>) [<xref rid="B63-jox-11-00013" ref-type="bibr">63</xref>]. Protein-bound antibiotics in nearly every member of the bleomycin family are sequestered by one or more ABC transporter-related genes contained in the bleomycin biosynthesis gene cluster [<xref rid="B30-jox-11-00013" ref-type="bibr">30</xref>]. Similarly, a gene, <italic toggle="yes">mrd</italic>, cloned from <italic toggle="yes">Streptomyces lavendulae</italic> was reported to confer resistance to mitomycin C (MC) in both <italic toggle="yes">Streptomyces lividans</italic> and <italic toggle="yes">E. coli</italic>; characterization of the protein MRD further revealed that it specifically binds to the drug MC and prevents its activation. Furthermore, three immunity proteins, namely MlbQ, MlbY, and MlbZ, encoded in the lantibiotic NAI-107 biosynthetic gene cluster were found to contribute to immunity in the lantibiotic producer strain Microbispora ATCC PTA-5024 toward its antibiotic; the protein MlbQ was proposed to bind the cognate lantibiotic [<xref rid="B33-jox-11-00013" ref-type="bibr">33</xref>].</p></sec><sec id="sec7-jox-11-00013"><title>7. ESKAPE Pathogens</title><p><italic toggle="yes">Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa</italic>, and <italic toggle="yes">Enterobacter</italic> spp. are the antibiotic resistant pathogens which are collectively known as ESKAPE. ESKAPE is responsible for causing huge infectious diseases [<xref rid="B40-jox-11-00013" ref-type="bibr">40</xref>]. Their ability to form biofilm is the best protection strategy against antimicrobial agents. The study of ESKAPE pathogens in clinical and non-clinical cases, their transfer of genetic material, resistance mechanism, and capability for biofilm formation can be the key for the development of new diagnostics and strategies. ESKAPE pathogens are important to study, as they show a high degree of drug resistance and can easily escape different therapeutic tools. They are responsible for nosocomial infection with high mortality rates. COVID-19 patients in the intensive care unit (ICU) often face secondary infection or co-infection due to ESKAPE pathogens [<xref rid="B65-jox-11-00013" ref-type="bibr">65</xref>]. These pathogens are responsible for the development of ventilator-associated pneumonia (VAP) [<xref rid="B40-jox-11-00013" ref-type="bibr">40</xref>]. Hospital equipment and surfaces require proper sterilization to overcome the infection caused by ESKAPE. Various research implies that antimicrobial peptides (AMPs), human milk oligosaccharides (HMOs), metal nanoparticles, antibacterial polymers, etc., show promising result against ESKAPE pathogens, but only in the laboratory system [<xref rid="B66-jox-11-00013" ref-type="bibr">66</xref>,<xref rid="B67-jox-11-00013" ref-type="bibr">67</xref>]. Modern approaches and specific drugs must be taken into account to fight ESKAPE pathogens. ESKAPE pathogens share a similar mode of drug resistant mechanisms like other bacteria, and they include drug inactivation, modification of target site, and reduction of antibiotic accumulation [<xref rid="B67-jox-11-00013" ref-type="bibr">67</xref>]. Apart from this, their biofilm forming ability on surfaces makes them more prone to drug resistance [<xref rid="B66-jox-11-00013" ref-type="bibr">66</xref>]. Genetic elements such as efflux pumps, integrons, transposons, and others are present in ESKAPE pathogens, which are responsible for their drug resistance capability. All of the ESKAPE pathogens are responsible for coinfection with SARS-CoV-2. However, A. baumannii showed a high level of drug resistance in the COVID-19 pandemic [<xref rid="B40-jox-11-00013" ref-type="bibr">40</xref>,<xref rid="B65-jox-11-00013" ref-type="bibr">65</xref>].</p></sec><sec id="sec8-jox-11-00013"><title>8. Global and Developing Countries Scenario</title><p>Antibiotic resistance is considered a global economic burden. In the year 2018, the Global Antimicrobial Surveillance System (GLASS), a part of the WHO, declared a huge list of resistant bacteria (<italic toggle="yes">E. coli</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">S. aureus</italic>, and <italic toggle="yes">Streptococcus pneumoniae</italic> many more) widely spread among various countries. In this present scenario, several countries are presenting data regarding antibiotic surveillance to the WHO, while several face major problems in this surveillance program. The WHO is playing a significant role in promoting this study for the countries such as Kenya, Tunisia, Cambodia, Afghanistan, etc. GLASS can be considered a breakthrough to combat the global threat of antimicrobial resistance. Strong surveillance programs across different global and national locations may help in the enrichment of data and to reduce the burden of AMR [<xref rid="B56-jox-11-00013" ref-type="bibr">56</xref>,<xref rid="B68-jox-11-00013" ref-type="bibr">68</xref>]. Countries such as Pakistan, Thailand, Bangladesh, Nigeria, Nepal, and Brazil are facing huge antibacterial resistance due to various transmission sources including poultry, the environment, humans, etc. [<xref rid="B68-jox-11-00013" ref-type="bibr">68</xref>,<xref rid="B69-jox-11-00013" ref-type="bibr">69</xref>]. An anticipated death of around 3 million people by 2050 may be caused in continents like Asia, Africa, and North America due to antibiotic resistance. Creating awareness and educating people is the most prime focus of researchers/scientists for controlling the burden of antibiotic resistance. The WHO states that irrespective of the COVID-19 pandemic situation, many parts of the world are reporting a detailed surveillance site of AMR. All of this information covered by GLASS will provide a better opportunity to tackle health threats [<xref rid="B68-jox-11-00013" ref-type="bibr">68</xref>]. Apart from GLASS, the Global Antibiotic Research and Development Partnership (GARDP) and Interagency Coordination Group on Antimicrobial Resistance (IACG) are also working with the WHO for the improvement and development of antibiotics, and the implementation of global action plan to combat the present scenario. The WHO and governments of different countries can create awareness regarding hygiene maintain protocol among the common peoples. This safety measure along with knowledge of antimicrobial stewardship programs is very important in low- and middle-income countries [<xref rid="B70-jox-11-00013" ref-type="bibr">70</xref>].</p><p>Various measures should be adopted to tackle the problem of antibiotic resistance; however, the problem is persistent, and failure to combat the issue to date has been a matter of social, medical, and economic concern worldwide [<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>]. Even successful modern therapeutics would be impossible without the involvement of antibiotics. Thus, initiating significant research activities along with creating awareness and surveillance at the global level is urgently needed to resolve the issue. Very few new drugs are available in the market irrespective of the demand for new antibiotics [<xref rid="B71-jox-11-00013" ref-type="bibr">71</xref>]. The introduction of new antibiotics in the market of developing countries is very important to save the lives of a huge number of people [<xref rid="B9-jox-11-00013" ref-type="bibr">9</xref>].</p></sec><sec id="sec9-jox-11-00013"><title>9. Impact of COVID-19 Pandemic in AMR</title><p>With the exposure of the COVID-19 pandemic, the complication of drug resistance has increased, as the significant use of antibiotics in COVID-19 patients is a major area of concern [<xref rid="B72-jox-11-00013" ref-type="bibr">72</xref>]. For the treatment of COVID-19, the accelerated use of antibiotics, antiparasitic, and antiviral drugs has been performed [<xref rid="B73-jox-11-00013" ref-type="bibr">73</xref>], and this resulted in the spread of AMR. Initially, around 87.7% of COVID-19 patients were treated with antibiotics, whereas only 6.9% of patients were co-infected with bacteria or had a secondary infection. The unnecessary use of antibiotics must be reduced; increasing the rate of vaccination and other treatment options is necessary to combat COVID-19. In fact, few or a small number of COVID-19 patients require antibiotics for bacterial co-infection treatment, whereas a huge number of patients are receiving antimicrobials. Awareness and warnings regarding the increased rate of antimicrobial resistance with elevation in the case of COVID-19 patients all over the world must be put into immediate action. With a sudden outbreak of the COVID-19 pandemic globally, and due to the unavailability of effective medicines or vaccines, handling this situation is highly challenging, especially in the low- and middle-income countries [<xref rid="B39-jox-11-00013" ref-type="bibr">39</xref>,<xref rid="B74-jox-11-00013" ref-type="bibr">74</xref>]. Thus, the consumption of antibiotics and other antimicrobial agents has been increasing with the dissipation of COVID-19. In some cases, secondary bacterial infections were associated with this viral disease, and thus antibiotics were used to treat patients [<xref rid="B75-jox-11-00013" ref-type="bibr">75</xref>]. Initial studies by researchers [<xref rid="B76-jox-11-00013" ref-type="bibr">76</xref>,<xref rid="B77-jox-11-00013" ref-type="bibr">77</xref>], stated that COVID-19 patients were affected by different bacterial infections and thus antibiotic consumption was high. Thus, consumption of antibiotics by the COVID-19 patients without prior identification of bacterial infections must not be recommended and should be stopped immediately. Effective treatment procedures for COVID-19 patients are under research and successful analysis of the treatment options may enhance the use of appropriate and specific drugs [<xref rid="B78-jox-11-00013" ref-type="bibr">78</xref>,<xref rid="B79-jox-11-00013" ref-type="bibr">79</xref>]. According to WHO guidelines, the use of antibiotics for treatment of suspected or mild COVID-19 patients is not recommended without confirmed bacterial infection [<xref rid="B39-jox-11-00013" ref-type="bibr">39</xref>]. However, the use of antimicrobials for severe COVID-19 patients is used to combat the pathogens [<xref rid="B78-jox-11-00013" ref-type="bibr">78</xref>]. COVID-19 patients are hospitalized regularly worldwide, and they suffer from secondary or co-infections [<xref rid="B75-jox-11-00013" ref-type="bibr">75</xref>]. Thus, antibiotic therapy remains the best choice of treatment [<xref rid="B80-jox-11-00013" ref-type="bibr">80</xref>]. Hospital and ventilator-acquired pneumonia (HAP/VAP) was found in COVID-19 patients [<xref rid="B10-jox-11-00013" ref-type="bibr">10</xref>]. Usage of antibiotics in COVID-19 patients in the hospital at the early stage of this pandemic has created a burden in respect to antibiotic resistance [<xref rid="B80-jox-11-00013" ref-type="bibr">80</xref>]. Proper disposal of COVID-19 waste, appropriate antimicrobial policy, and multi-sectional approaches can help to reduce the impact of the COVID-19 pandemic and AMR in the environment.</p></sec><sec id="sec10-jox-11-00013"><title>10. Epidemiology and Surveillance</title><p>To some extent, the modern healthcare system is responsible for the transmission of community-acquired antibiotic resistance. Antibiotic resistance has become a worldwide alarming issue, due to low price, easy availability, and irrational use of antibiotic drugs [<xref rid="B9-jox-11-00013" ref-type="bibr">9</xref>]. Scientists and medical authorities, as well as government is focusing on alternative treatment options such as passive immunization, administration of antibodies, and phage therapy [<xref rid="B14-jox-11-00013" ref-type="bibr">14</xref>]. Government and Policymakers must ensure National Action Plan, maintaining databank and detail surveillance for stewardship of antibiotics and their resistance [<xref rid="B81-jox-11-00013" ref-type="bibr">81</xref>]. Dissemination of information, development of new drugs and vaccines are vital in the present situation. Vaccination of animals is recommended, and appropriate antibiotics administration must be considered for animal welfare [<xref rid="B1-jox-11-00013" ref-type="bibr">1</xref>]. Elaborative research and surveillance regarding antimicrobial resistance patterns, infectious pathogen transmission, and their appropriate treatment options are of great importance to fight against COVID-19 pandemic and antimicrobial resistance [<xref rid="B10-jox-11-00013" ref-type="bibr">10</xref>,<xref rid="B72-jox-11-00013" ref-type="bibr">72</xref>].</p><sec id="sec10dot1-jox-11-00013"><title>10.1. Control Strategy of Antibiotic Resistance</title><p>Appropriate indication, dosage, means, and time of drug intake strictly according to medical advice is a necessary component for controlling antibiotic resistance. In addition, antibiotic resistance profiling of patients is recommended before prescribing antibiotics [<xref rid="B82-jox-11-00013" ref-type="bibr">82</xref>]. Moreover, strict implementation of infection control measures, proper hygiene and sanitation standards, and appropriate disposal or discharge of medical wastes must be ensured in hospitals and communities. All these control strategies must be regulated by strict government policies to ensure their implementation by the common people. Researchers believe that the application of computational biology in combination with nanotechnology can open new avenues to combat the problem of antibiotic resistance [<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>]. Pharmaceutical industries are currently aiming to develop new drugs that can fight against new resistant strains [<xref rid="B14-jox-11-00013" ref-type="bibr">14</xref>]. However, with the development of improved and novel pharmaceutical products, bacteria are also expanding their resistance to different avenues by modifying their molecular regulators. Knowingly or unknowingly, people in every corner of the world are excessively using antibiotics without proper medical concern. Furthermore, to overcome the issues of antibiotic resistance, the government must release ample funds as well as set new policies. Personalized medicine and appropriate antibiotic therapy for patients can be novel interventions for antibiotic resistances.</p><p>At an individual level, we can put some of our effort to combat the expansion of antibiotic resistance by using antibiotics only prescribed by doctors, restricting of overuse of antibiotics in the food and animal sector, and maintaining hygiene protocol. Control in antimicrobial resistance is important to mandate to overcome or reduce the impact of COVID-19. Management practices and strategies must be taken into account for restricted use of antimicrobials and biocide to tackle the problem of AMR, public health, and the environment. Encouraging hygiene measures but discouraging overuse of disinfectants and antimicrobials must be a scheme to overcome the problem of AMR along with the COVID-19 pandemic. Prescribing antibiotics, their proper use and behavioral change of people towards health management issues can be a strategy to fight antibiotic resistance [<xref rid="B6-jox-11-00013" ref-type="bibr">6</xref>,<xref rid="B39-jox-11-00013" ref-type="bibr">39</xref>]. Creating AMR awareness among the population of the developing countries must be undertaken together by the policymaker, researchers, and implementation teams [<xref rid="B83-jox-11-00013" ref-type="bibr">83</xref>]. With the advent of COVID-19, few hygienic measures such as hand washing, proper disinfection, and social distancing have developed among people of the world [<xref rid="B39-jox-11-00013" ref-type="bibr">39</xref>]. All of these measures in the near future will definitely help to reduce the spread of AMR. Along with this, the surveillance on use of antimicrobial agents, susceptibility profiling of bacterial infection, and the development of therapeutic measures for COVID-19 will help to focus on controlling the spread of both viral and bacterial infection [<xref rid="B82-jox-11-00013" ref-type="bibr">82</xref>].</p></sec><sec id="sec10dot2-jox-11-00013"><title>10.2. Therapeutic Interventions</title><p>Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) (<uri xlink:href="https://carb-x.org/">https://carb-x.org/</uri>), the Replenishing and Enabling the Pipeline for Anti-Infective Resistance (REPAIR) Impact Fund (<uri xlink:href="https://www.repair-impact-fund.com/">https://www.repair-impact-fund.com/</uri>), Global Antibiotic Research and Development Partnership (GARDP) have taken initiatives to develop new antimicrobials and other treatment options to encounter the problem of AMR [<xref rid="B10-jox-11-00013" ref-type="bibr">10</xref>,<xref rid="B40-jox-11-00013" ref-type="bibr">40</xref>,<xref rid="B84-jox-11-00013" ref-type="bibr">84</xref>]. According to the WHO pipeline report (2020), the new antibiotics are not sufficient to handle the rise of antimicrobial resistance. Application of different therapies including antibody or bacteriophage rather than antibiotics is suggested and recommended by WHO. For the development of an innovative and promising product to strengthen and accelerate the drive of antibiotic research AMR Action Fund and Antimicrobial Resistance Multi-Partner Trust Fund (AMR MPTF) was established. Surveillance systems in different countries of the world by GLASS will help to develop a new therapeutic intervention. In this pandemic situation, new normal living such as social distancing, reduced travel, and increased personal hygiene is the key to better lifestyle [<xref rid="B81-jox-11-00013" ref-type="bibr">81</xref>]. The development of mRNA vaccines and new diagnostic tools would be very effective [<xref rid="B39-jox-11-00013" ref-type="bibr">39</xref>]. New therapeutic intervention is important for carbapenem-resistant <italic toggle="yes">Enterobacteriaceae</italic> and <italic toggle="yes">A. baumannii</italic>. Secondary plants metabolites, probiotics, prebiotics, and others may be better alternative approaches for the treatment of diseases [<xref rid="B15-jox-11-00013" ref-type="bibr">15</xref>,<xref rid="B85-jox-11-00013" ref-type="bibr">85</xref>,<xref rid="B86-jox-11-00013" ref-type="bibr">86</xref>].</p><p>Focusing on identifying the gene/s responsible for resistance, followed by their detailed molecular analyses will help combat the problem. Thus, the accessibility of available information on bacterial genomes along with functional data for various antibiotic resistance genes will help in developing efficient preventive tools and diagnostic pathways. Culture-based identification techniques for bacterial isolates followed by antimicrobial susceptibility profiling are being extensively employed. However, these culture-based assays are associated with several drawbacks, such as their time-consuming nature and inaccurate interpretation. Since accurate and on-time analysis of the AMR profile is crucial, molecular approaches are considered suitable because of their superior sensitivity and specificity, rapidity, and ability to identify bacterial drug susceptibilities. Molecular tools can identify specific resistance mechanisms and aid in selecting the most effective antibiotics for patients. Molecular-based diagnostic tools can also reduce healthcare costs. Moreover, the speed and sensitivity of molecular-based approaches provide benefits in terms of time and accuracy. The extensive molecular characterization of antibiotic resistance genes is urgently required to develop novel therapeutic strategies for preventing life-threatening infections [<xref rid="B87-jox-11-00013" ref-type="bibr">87</xref>].</p><p>Gram-negative bacterial pathogens are at the most alarming state as they are becoming resistant to nearly every drug to some extent. Therefore, studying the transmission or spread of MDR gene/s is vital for analyzing transmission pathways and risk factors for infection. One of the most important challenges is to precisely identify the drug-resistant for a patient in a short period time and cost-effective manner. Since the tracking of various resistance mechanisms or gene/s responsible for resistance is important, proper database and diagnostic techniques should be maintained, and wise use of antibiotics by improving its prescribing/stewardship should be emphasized [<xref rid="B10-jox-11-00013" ref-type="bibr">10</xref>,<xref rid="B82-jox-11-00013" ref-type="bibr">82</xref>].</p></sec></sec><sec id="sec11-jox-11-00013"><title>11. In Silico Analysis</title><p>In silico analysis for research regarding antimicrobial resistance will open a new avenue for scientists and the pharmaceutical industry as well as policymakers [<xref rid="B88-jox-11-00013" ref-type="bibr">88</xref>]. Molecular docking and homology modeling of the available drugs can be easily investigated [<xref rid="B69-jox-11-00013" ref-type="bibr">69</xref>,<xref rid="B89-jox-11-00013" ref-type="bibr">89</xref>]. In silico study will also help in understanding the drug resistant mechanism, prediction of traits responsible for AMR, protein-protein interaction, changes in structural conformation and analysis of mutational hotspot region [<xref rid="B90-jox-11-00013" ref-type="bibr">90</xref>]. Apart from this bioinformatics tools and software will help in the analysis of serogroup, antigenic profiling, identification of plasmid and antibiotic resistance genes [<xref rid="B22-jox-11-00013" ref-type="bibr">22</xref>]. Application of metagenomics, antibiotic resistance databases, and machine learning tools will help to predict the resistance pattern and profile [<xref rid="B22-jox-11-00013" ref-type="bibr">22</xref>]. Therefore, all this information can be useful in research related to AMR and its treatment options. Whole-genome sequencing (WGS) and/or next-generation sequencing (NGS) should be effective for surveillance of AMR gene in bacteria and this information will guide in the intervention of AMR [<xref rid="B68-jox-11-00013" ref-type="bibr">68</xref>,<xref rid="B90-jox-11-00013" ref-type="bibr">90</xref>,<xref rid="B91-jox-11-00013" ref-type="bibr">91</xref>]. Different web-based tools or software can be developed for easy and rapid detection of determinants or genetic elements responsible for MDR [<xref rid="B2-jox-11-00013" ref-type="bibr">2</xref>]. Transcriptomic and metagenomics studies are emerging fields of advanced science, therefore using these techniques for drug discovery and curbing antimicrobial resistance is the forte. Personalized drugs can also be designed using in silico approaches [<xref rid="B22-jox-11-00013" ref-type="bibr">22</xref>].</p></sec><sec sec-type="conclusions" id="sec12-jox-11-00013"><title>12. Conclusions</title><p>Irrespective of the measures taken by the WHO and the CDC, many people in different parts of the world are not aware of antibiotic resistance and its consequences. The problem is not only limited to the healthcare sector, but also an increasing thrust for the world economy. With the emergence of MDR, PDR and other types of resistant bacteria globally, treatment option in medical science is facing various hurdles. The shortage of new antimicrobial agents is a major concern in healthcare systems. Therefore, immediate enforcement of epidemiological and surveillance studies is required for the analysis and prevention of antibiotic resistance. Sufficient knowledge and information can be the key to controlling MDR. Strict government policies and regulations throughout the world are also essential for monitoring the use of antibiotics and other related aspects. Finally, multidisciplinary approaches must be considered to eliminate the serious threat caused by MDR. Collaborative studies of computational biology with nanotechnology can open new avenues to combat the problem of antibiotic resistance. New knowledge on MGEs could enhance understanding of the genesis of variants and pathogen evolution. It may also help in developing potential therapeutic interventions for pathogen spreading and for restricting the growth of pathogenic strains. Additionally, a model for decreasing antibiotic consumption can be developed by knowing the transmission rate of antibiotic resistance from animals to humans.</p><p>The goal of the authors is to provide everyone with some basic ideas regarding the appropriate usage of any antimicrobial agents. This study has focused on the different aspects of antibiotic resistance and its associative problem with public health. Few conceptions of molecular mechanisms of antibiotic resistance and emergence of antibiotic resistant superbugs were discussed to provide some insights for the formulation of new treatment options. The authors also tried to outline the global impact of the COVID-19 pandemic on antibiotic resistance. The review provides an overview regarding the importance of antibiotic resistance from an enlarged perspective, its arising challenges and multi-sectional strategy that may help the government, researchers, and other people to tackle this vital issue.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank University of Calcutta (Department of Microbiology) and ICMR-NICED (Virology Unit), Kolkata, West Bengal, India for providing laboratory space, library access, high-speed internet, and computational laboratory facilities.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>M.S.&#x02014;Conceptualization, Formal Analysis and Investigation, Writing&#x02014;Original Draft Preparation. A.S.&#x02014;Writing&#x02014;Review and Editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>No funding was received to assist with the preparation of this manuscript. No funding was received for conducting this study. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors have no relevant financial or non-financial interests to disclose. The authors have no conflicts of interest to declare that are relevant to the content of this article. The authors have no financial or proprietary interests in any material discussed in this article.</p></notes><ref-list><title>References</title><ref id="B1-jox-11-00013"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prestinaci</surname><given-names>F.</given-names></name>
<name><surname>Pezzotti</surname><given-names>P.</given-names></name>
<name><surname>Pantosti</surname><given-names>A.</given-names></name>
</person-group><article-title>Antimicrobial Resistance: A Global Multifaceted Phenomenon</article-title><source>Pathog. Glob. Health</source><year>2015</year><volume>109</volume><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1179/2047773215Y.0000000030</pub-id><pub-id pub-id-type="pmid">26343252</pub-id></element-citation></ref><ref id="B2-jox-11-00013"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johansson</surname><given-names>M.H.K.</given-names></name>
<name><surname>Bortolaia</surname><given-names>V.</given-names></name>
<name><surname>Tansirichaiya</surname><given-names>S.</given-names></name>
<name><surname>Aarestrup</surname><given-names>F.M.</given-names></name>
<name><surname>Roberts</surname><given-names>A.P.</given-names></name>
<name><surname>Petersen</surname><given-names>T.N.</given-names></name>
</person-group><article-title>Detection of Mobile Genetic Elements Associated with Antibiotic Resistance in Salmonella Enterica Using a Newly Developed Web Tool: MobileElementFinder</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>76</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa390</pub-id></element-citation></ref><ref id="B3-jox-11-00013"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Majumder</surname><given-names>M.A.A.</given-names></name>
<name><surname>Rahman</surname><given-names>S.</given-names></name>
<name><surname>Cohall</surname><given-names>D.</given-names></name>
<name><surname>Bharatha</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>K.</given-names></name>
<name><surname>Haque</surname><given-names>M.</given-names></name>
<name><surname>Gittens-St Hilaire</surname><given-names>M.</given-names></name>
</person-group><article-title>Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health</article-title><source>Infect. Drug Resist.</source><year>2020</year><volume>13</volume><fpage>4713</fpage><lpage>4738</lpage><pub-id pub-id-type="doi">10.2147/IDR.S290835</pub-id><?supplied-pmid 33402841?><pub-id pub-id-type="pmid">33402841</pub-id></element-citation></ref><ref id="B4-jox-11-00013"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ranjalkar</surname><given-names>J.</given-names></name>
<name><surname>Chandy</surname><given-names>S.</given-names></name>
</person-group><article-title>India&#x02019;s National Action Plan for Antimicrobial Resistance&#x02014;An Overview of the Context, Status, and Way Ahead</article-title><source>J. Fam. Med. Prim. Care</source><year>2019</year><volume>8</volume><fpage>1828</fpage><pub-id pub-id-type="doi">10.4103/jfmpc.jfmpc_275_19</pub-id></element-citation></ref><ref id="B5-jox-11-00013"><label>5.</label><element-citation publication-type="webpage"><article-title>World Health Organization Director-General&#x02019;s Opening Remarks at the Media Briefing on COVID-19</article-title><year>2020</year><comment>Available online: <ext-link xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19-11-march-2020" ext-link-type="uri">https://www.who.int/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19-11-march-2020</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-03-11">(accessed on 11 March 2020)</date-in-citation></element-citation></ref><ref id="B6-jox-11-00013"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rezasoltani</surname><given-names>S.</given-names></name>
<name><surname>Yadegar</surname><given-names>A.</given-names></name>
<name><surname>Hatami</surname><given-names>B.</given-names></name>
<name><surname>Asadzadeh Aghdaei</surname><given-names>H.</given-names></name>
<name><surname>Zali</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Antimicrobial Resistance as a Hidden Menace Lurking behind the COVID-19 Outbreak: The Global Impacts of Too Much Hygiene on AMR</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><pub-id pub-id-type="doi">10.3389/fmicb.2020.590683</pub-id><?supplied-pmid 33384670?><pub-id pub-id-type="pmid">33384670</pub-id></element-citation></ref><ref id="B7-jox-11-00013"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cucinotta</surname><given-names>D.</given-names></name>
<name><surname>Vanelli</surname><given-names>M.</given-names></name>
</person-group><article-title>WHO Declares COVID-19 a Pandemic</article-title><source>Acta Bio-Med. Atenei Parm.</source><year>2020</year><volume>91</volume><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.23750/abm.v91i1.9397</pub-id></element-citation></ref><ref id="B8-jox-11-00013"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adhanom Ghebreyesus</surname><given-names>T.</given-names></name>
</person-group><article-title>Addressing Mental Health Needs: An Integral Part of COVID-19 Response</article-title><source>World Psychiatry</source><year>2020</year><volume>19</volume><fpage>129</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1002/wps.20768</pub-id><?supplied-pmid 32394569?><pub-id pub-id-type="pmid">32394569</pub-id></element-citation></ref><ref id="B9-jox-11-00013"><label>9.</label><element-citation publication-type="webpage"><article-title>World Antimicrobial Awareness Week</article-title><year>2020</year><comment>Available online: <ext-link xlink:href="https://www.who.int/campaigns/world-antibiotic-awareness-week" ext-link-type="uri">https://www.who.int/campaigns/world-antibiotic-awareness-week</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-11-18">(accessed on 18 November 2020)</date-in-citation></element-citation></ref><ref id="B10-jox-11-00013"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pelfrene</surname><given-names>E.</given-names></name>
<name><surname>Botgros</surname><given-names>R.</given-names></name>
<name><surname>Cavaleri</surname><given-names>M.</given-names></name>
</person-group><article-title>Antimicrobial Multidrug Resistance in the Era of COVID-19: A Forgotten Plight?</article-title><source>Antimicrob. Resist. Infect. Control</source><year>2021</year><volume>10</volume><pub-id pub-id-type="doi">10.1186/s13756-021-00893-z</pub-id></element-citation></ref><ref id="B11-jox-11-00013"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Exner</surname><given-names>M.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>S.</given-names></name>
<name><surname>Christiansen</surname><given-names>B.</given-names></name>
<name><surname>Gebel</surname><given-names>J.</given-names></name>
<name><surname>Goroncy-Bermes</surname><given-names>P.</given-names></name>
<name><surname>Hartemann</surname><given-names>P.</given-names></name>
<name><surname>Heeg</surname><given-names>P.</given-names></name>
<name><surname>Ilschner</surname><given-names>C.</given-names></name>
<name><surname>Kramer</surname><given-names>A.</given-names></name>
<name><surname>Larson</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?</article-title><source>GMS Hyg. Infect. Control</source><year>2017</year><volume>12</volume><pub-id pub-id-type="doi">10.3205/dgkh000290</pub-id></element-citation></ref><ref id="B12-jox-11-00013"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Das</surname><given-names>B.</given-names></name>
<name><surname>Verma</surname><given-names>J.</given-names></name>
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>Ghosh</surname><given-names>A.</given-names></name>
<name><surname>Ramamurthy</surname><given-names>T.</given-names></name>
</person-group><article-title>Antibiotic Resistance in Vibrio Cholerae: Understanding the Ecology of Resistance Genes and Mechanisms</article-title><source>Vaccine</source><year>2019</year><volume>38</volume><issue>(Suppl. 1)</issue><fpage>A83</fpage><lpage>A92</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.06.031</pub-id><pub-id pub-id-type="pmid">31272870</pub-id></element-citation></ref><ref id="B13-jox-11-00013"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Partridge</surname><given-names>S.R.</given-names></name>
<name><surname>Kwong</surname><given-names>S.M.</given-names></name>
<name><surname>Firth</surname><given-names>N.</given-names></name>
<name><surname>Jensen</surname><given-names>S.O.</given-names></name>
</person-group><article-title>Mobile Genetic Elements Associated with Antimicrobial Resistance</article-title><source>Clin. Microbiol. Rev.</source><year>2018</year><volume>31</volume><pub-id pub-id-type="doi">10.1128/CMR.00088-17</pub-id></element-citation></ref><ref id="B14-jox-11-00013"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baker</surname><given-names>S.J.</given-names></name>
<name><surname>Payne</surname><given-names>D.J.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
<name><surname>De Gregorio</surname><given-names>E.</given-names></name>
</person-group><article-title>Technologies to Address Antimicrobial Resistance</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>12887</fpage><lpage>12895</lpage><pub-id pub-id-type="doi">10.1073/pnas.1717160115</pub-id><pub-id pub-id-type="pmid">30559181</pub-id></element-citation></ref><ref id="B15-jox-11-00013"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Breijyeh</surname><given-names>Z.</given-names></name>
<name><surname>Jubeh</surname><given-names>B.</given-names></name>
<name><surname>Karaman</surname><given-names>R.</given-names></name>
</person-group><article-title>Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>1340</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25061340</pub-id></element-citation></ref><ref id="B16-jox-11-00013"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ayukekbong</surname><given-names>J.A.</given-names></name>
<name><surname>Ntemgwa</surname><given-names>M.</given-names></name>
<name><surname>Atabe</surname><given-names>A.N.</given-names></name>
</person-group><article-title>The Threat of Antimicrobial Resistance in Developing Countries: Causes and Control Strategies</article-title><source>Antimicrob. Resist. Infect. Control</source><year>2017</year><volume>6</volume><pub-id pub-id-type="doi">10.1186/s13756-017-0208-x</pub-id><?supplied-pmid 28515903?><pub-id pub-id-type="pmid">28515903</pub-id></element-citation></ref><ref id="B17-jox-11-00013"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gould</surname><given-names>K.</given-names></name>
</person-group><article-title>Antibiotics: From Prehistory to the Present Day</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>572</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv484</pub-id><?supplied-pmid 26851273?><pub-id pub-id-type="pmid">26851273</pub-id></element-citation></ref><ref id="B18-jox-11-00013"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Unemo</surname><given-names>M.</given-names></name>
<name><surname>Shafer</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Antimicrobial Resistance in Neisseria Gonorrhoeae in the 21st Century: Past, Evolution, and Future</article-title><source>Clin. Microbiol. Rev.</source><year>2014</year><volume>27</volume><fpage>587</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1128/CMR.00010-14</pub-id><pub-id pub-id-type="pmid">24982323</pub-id></element-citation></ref><ref id="B19-jox-11-00013"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>P.-Y.</given-names></name>
<name><surname>Huang</surname><given-names>A.-H.</given-names></name>
<name><surname>Lai</surname><given-names>C.-H.</given-names></name>
<name><surname>Lin</surname><given-names>H.-F.</given-names></name>
<name><surname>Lin</surname><given-names>T.-M.</given-names></name>
<name><surname>Ho</surname><given-names>C.-H.</given-names></name>
</person-group><article-title>Extensively Drug-Resistant Haemophilus Influenzae&#x02014;Emergence, Epidemiology, Risk Factors, and Regimen</article-title><source>BMC Microbiol.</source><year>2020</year><volume>20</volume><pub-id pub-id-type="doi">10.1186/s12866-020-01785-9</pub-id></element-citation></ref><ref id="B20-jox-11-00013"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossiter</surname><given-names>S.E.</given-names></name>
<name><surname>Fletcher</surname><given-names>M.H.</given-names></name>
<name><surname>Wuest</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Natural Products as Platforms to Overcome Antibiotic Resistance</article-title><source>Chem. Rev.</source><year>2017</year><volume>117</volume><fpage>12415</fpage><lpage>12474</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.7b00283</pub-id><pub-id pub-id-type="pmid">28953368</pub-id></element-citation></ref><ref id="B21-jox-11-00013"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davies</surname><given-names>J.</given-names></name>
<name><surname>Davies</surname><given-names>D.</given-names></name>
</person-group><article-title>Origins and Evolution of Antibiotic Resistance</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2010</year><volume>74</volume><fpage>417</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00016-10</pub-id><pub-id pub-id-type="pmid">20805405</pub-id></element-citation></ref><ref id="B22-jox-11-00013"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ndagi</surname><given-names>U.</given-names></name>
<name><surname>Falaki</surname><given-names>A.A.</given-names></name>
<name><surname>Abdullahi</surname><given-names>M.</given-names></name>
<name><surname>Lawal</surname><given-names>M.M.</given-names></name>
<name><surname>Soliman</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Antibiotic Resistance: Bioinformatics-Based Understanding as a Functional Strategy for Drug Design</article-title><source>RSC Adv.</source><year>2020</year><volume>10</volume><fpage>18451</fpage><lpage>18468</lpage><pub-id pub-id-type="doi">10.1039/D0RA01484B</pub-id></element-citation></ref><ref id="B23-jox-11-00013"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doron</surname><given-names>S.</given-names></name>
<name><surname>Gorbach</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Bacterial Infections: Overview</article-title><source>Int. Encycl. Public Health</source><year>2008</year><fpage>273</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/B978-012373960-5.00596-7</pub-id></element-citation></ref><ref id="B24-jox-11-00013"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ventola</surname><given-names>C.L.</given-names></name>
</person-group><article-title>The antibiotic resistance crisis: Part 1: Causes and threats</article-title><source>Pharm. Ther.</source><year>2015</year><volume>40</volume><fpage>277</fpage><lpage>283</lpage></element-citation></ref><ref id="B25-jox-11-00013"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kadri</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Key Takeaways from the U.S. CDC&#x02019;s 2019 Antibiotic Resistance Threats Report for Frontline Providers</article-title><source>Crit. Care Med.</source><year>2020</year><volume>48</volume><fpage>939</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000004371</pub-id><?supplied-pmid 32282351?><pub-id pub-id-type="pmid">32282351</pub-id></element-citation></ref><ref id="B26-jox-11-00013"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kyriakidis</surname><given-names>I.</given-names></name>
<name><surname>Vasileiou</surname><given-names>E.</given-names></name>
<name><surname>Pana</surname><given-names>Z.D.</given-names></name>
<name><surname>Tragiannidis</surname><given-names>A.</given-names></name>
</person-group><article-title>Acinetobacter Baumannii Antibiotic Resistance Mechanisms</article-title><source>Pathogens</source><year>2021</year><volume>10</volume><elocation-id>373</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10030373</pub-id><pub-id pub-id-type="pmid">33808905</pub-id></element-citation></ref><ref id="B27-jox-11-00013"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magiorakos</surname><given-names>A.-P.</given-names></name>
<name><surname>Srinivasan</surname><given-names>A.</given-names></name>
<name><surname>Carey</surname><given-names>R.B.</given-names></name>
<name><surname>Carmeli</surname><given-names>Y.</given-names></name>
<name><surname>Falagas</surname><given-names>M.E.</given-names></name>
<name><surname>Giske</surname><given-names>C.G.</given-names></name>
<name><surname>Harbarth</surname><given-names>S.</given-names></name>
<name><surname>Hindler</surname><given-names>J.F.</given-names></name>
<name><surname>Kahlmeter</surname><given-names>G.</given-names></name>
<name><surname>Olsson-Liljequist</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance</article-title><source>Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.</source><year>2012</year><volume>18</volume><fpage>268</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03570.x</pub-id></element-citation></ref><ref id="B28-jox-11-00013"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alkofide</surname><given-names>H.</given-names></name>
<name><surname>Alhammad</surname><given-names>A.M.</given-names></name>
<name><surname>Alruwaili</surname><given-names>A.</given-names></name>
<name><surname>Aldemerdash</surname><given-names>A.</given-names></name>
<name><surname>Almangour</surname><given-names>T.A.</given-names></name>
<name><surname>Alsuwayegh</surname><given-names>A.</given-names></name>
<name><surname>Almoqbel</surname><given-names>D.</given-names></name>
<name><surname>Albati</surname><given-names>A.</given-names></name>
<name><surname>Alsaud</surname><given-names>A.</given-names></name>
<name><surname>Enani</surname><given-names>M.</given-names></name>
</person-group><article-title>Multidrug-Resistant and Extensively Drug-Resistant Enterobacteriaceae: Prevalence, Treatments, and Outcomes&#x02014;A Retrospective Cohort Study</article-title><source>Infect. Drug Resist.</source><year>2020</year><volume>13</volume><fpage>4653</fpage><lpage>4662</lpage><pub-id pub-id-type="doi">10.2147/IDR.S283488</pub-id><pub-id pub-id-type="pmid">33380815</pub-id></element-citation></ref><ref id="B29-jox-11-00013"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Folgori</surname><given-names>L.</given-names></name>
<name><surname>Ellis</surname><given-names>S.J.</given-names></name>
<name><surname>Bielicki</surname><given-names>J.A.</given-names></name>
<name><surname>Heath</surname><given-names>P.T.</given-names></name>
<name><surname>Sharland</surname><given-names>M.</given-names></name>
<name><surname>Balasegaram</surname><given-names>M.</given-names></name>
</person-group><article-title>Tackling Antimicrobial Resistance in Neonatal Sepsis</article-title><source>Lancet Glob. Health</source><year>2017</year><volume>5</volume><fpage>e1066</fpage><lpage>e1068</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(17)30362-5</pub-id><pub-id pub-id-type="pmid">29025624</pub-id></element-citation></ref><ref id="B30-jox-11-00013"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peterson</surname><given-names>E.</given-names></name>
<name><surname>Kaur</surname><given-names>P.</given-names></name>
</person-group><article-title>Antibiotic Resistance Mechanisms in Bacteria: Relationships between Resistance Determinants of Antibiotic Producers, Environmental Bacteria, and Clinical Pathogens</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><pub-id pub-id-type="doi">10.3389/fmicb.2018.02928</pub-id></element-citation></ref><ref id="B31-jox-11-00013"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajpara</surname><given-names>N.</given-names></name>
<name><surname>Kutar</surname><given-names>B.M.R.N.S.</given-names></name>
<name><surname>Sinha</surname><given-names>R.</given-names></name>
<name><surname>Nag</surname><given-names>D.</given-names></name>
<name><surname>Koley</surname><given-names>H.</given-names></name>
<name><surname>Ramamurthy</surname><given-names>T.</given-names></name>
<name><surname>Bhardwaj</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Role of Integrons, Plasmids and SXT Elements in Multidrug Resistance of Vibrio Cholerae and Providencia Vermicola Obtained from a Clinical Isolate of Diarrhea</article-title><source>Front. Microbiol.</source><year>2015</year><volume>6</volume><pub-id pub-id-type="doi">10.3389/fmicb.2015.00057</pub-id></element-citation></ref><ref id="B32-jox-11-00013"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Munita</surname><given-names>J.M.</given-names></name>
<name><surname>Arias</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Mechanisms of Antibiotic Resistance</article-title><source>Microbiol. Spectr.</source><year>2016</year><volume>4</volume><fpage>481</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1128/microbiolspec.VMBF-0016-2015</pub-id></element-citation></ref><ref id="B33-jox-11-00013"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pozzi</surname><given-names>R.</given-names></name>
<name><surname>Coles</surname><given-names>M.</given-names></name>
<name><surname>Linke</surname><given-names>D.</given-names></name>
<name><surname>Kulik</surname><given-names>A.</given-names></name>
<name><surname>Nega</surname><given-names>M.</given-names></name>
<name><surname>Wohlleben</surname><given-names>W.</given-names></name>
<name><surname>Stegmann</surname><given-names>E.</given-names></name>
</person-group><article-title>Distinct Mechanisms Contribute to Immunity in the Lantibiotic NAI-107 Producer StrainMicrobispora|ATCC PTA-5024</article-title><source>Environ. Microbiol.</source><year>2015</year><volume>18</volume><fpage>118</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1111/1462-2920.12892</pub-id><pub-id pub-id-type="pmid">25923468</pub-id></element-citation></ref><ref id="B34-jox-11-00013"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aslam</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Arshad</surname><given-names>M.I.</given-names></name>
<name><surname>Khurshid</surname><given-names>M.</given-names></name>
<name><surname>Muzammil</surname><given-names>S.</given-names></name>
<name><surname>Rasool</surname><given-names>M.H.</given-names></name>
<name><surname>Nisar</surname><given-names>M.A.</given-names></name>
<name><surname>Alvi</surname><given-names>R.F.</given-names></name>
<name><surname>Aslam</surname><given-names>M.A.</given-names></name>
<name><surname>Qamar</surname><given-names>M.U.</given-names></name>
<etal/>
</person-group><article-title>Antibiotic Resistance: A Rundown of a Global Crisis</article-title><source>Infect. Drug Resist.</source><year>2018</year><volume>11</volume><fpage>1645</fpage><lpage>1658</lpage><pub-id pub-id-type="doi">10.2147/IDR.S173867</pub-id><pub-id pub-id-type="pmid">30349322</pub-id></element-citation></ref><ref id="B35-jox-11-00013"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>von Wintersdorff</surname><given-names>C.J.H.</given-names></name>
<name><surname>Penders</surname><given-names>J.</given-names></name>
<name><surname>van Niekerk</surname><given-names>J.M.</given-names></name>
<name><surname>Mills</surname><given-names>N.D.</given-names></name>
<name><surname>Majumder</surname><given-names>S.</given-names></name>
<name><surname>van Alphen</surname><given-names>L.B.</given-names></name>
<name><surname>Savelkoul</surname><given-names>P.H.M.</given-names></name>
<name><surname>Wolffs</surname><given-names>P.F.G.</given-names></name>
</person-group><article-title>Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer</article-title><source>Front. Microbiol.</source><year>2016</year><volume>7</volume><pub-id pub-id-type="doi">10.3389/fmicb.2016.00173</pub-id></element-citation></ref><ref id="B36-jox-11-00013"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogawara</surname><given-names>H.</given-names></name>
</person-group><article-title>Comparison of Antibiotic Resistance Mechanisms in Antibiotic-Producing and Pathogenic Bacteria</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>3430</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24193430</pub-id></element-citation></ref><ref id="B37-jox-11-00013"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manyi-Loh</surname><given-names>C.</given-names></name>
<name><surname>Mamphweli</surname><given-names>S.</given-names></name>
<name><surname>Meyer</surname><given-names>E.</given-names></name>
<name><surname>Okoh</surname><given-names>A.</given-names></name>
</person-group><article-title>Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>795</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23040795</pub-id><?supplied-pmid 29601469?><pub-id pub-id-type="pmid">29601469</pub-id></element-citation></ref><ref id="B38-jox-11-00013"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vidovic</surname><given-names>N.</given-names></name>
<name><surname>Vidovic</surname><given-names>S.</given-names></name>
</person-group><article-title>Antimicrobial Resistance and Food Animals: Influence of Livestock Environment on the Emergence and Dissemination of Antimicrobial Resistance</article-title><source>Antibiotics</source><year>2020</year><volume>9</volume><elocation-id>52</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics9020052</pub-id></element-citation></ref><ref id="B39-jox-11-00013"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rusic</surname><given-names>D.</given-names></name>
<name><surname>Vilovic</surname><given-names>M.</given-names></name>
<name><surname>Bukic</surname><given-names>J.</given-names></name>
<name><surname>Leskur</surname><given-names>D.</given-names></name>
<name><surname>Seselja Perisin</surname><given-names>A.</given-names></name>
<name><surname>Kumric</surname><given-names>M.</given-names></name>
<name><surname>Martinovic</surname><given-names>D.</given-names></name>
<name><surname>Petric</surname><given-names>A.</given-names></name>
<name><surname>Modun</surname><given-names>D.</given-names></name>
<name><surname>Bozic</surname><given-names>J.</given-names></name>
</person-group><article-title>Implications of COVID-19 Pandemic on the Emergence of Antimicrobial Resistance: Adjusting the Response to Future Outbreaks</article-title><source>Life</source><year>2021</year><volume>11</volume><elocation-id>220</elocation-id><pub-id pub-id-type="doi">10.3390/life11030220</pub-id><?supplied-pmid 33801799?><pub-id pub-id-type="pmid">33801799</pub-id></element-citation></ref><ref id="B40-jox-11-00013"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poulin-Laprade</surname><given-names>D.</given-names></name>
<name><surname>Matteau</surname><given-names>D.</given-names></name>
<name><surname>Jacques</surname><given-names>P.-&#x000c9;.</given-names></name>
<name><surname>Rodrigue</surname><given-names>S.</given-names></name>
<name><surname>Burrus</surname><given-names>V.</given-names></name>
</person-group><article-title>Transfer Activation of SXT/R391 Integrative and Conjugative Elements: Unraveling the SetCD Regulon</article-title><source>Nucleic Acids Res.</source><year>2015</year><volume>43</volume><fpage>2045</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv071</pub-id><pub-id pub-id-type="pmid">25662215</pub-id></element-citation></ref><ref id="B41-jox-11-00013"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spagnoletti</surname><given-names>M.</given-names></name>
<name><surname>Ceccarelli</surname><given-names>D.</given-names></name>
<name><surname>Rieux</surname><given-names>A.</given-names></name>
<name><surname>Fondi</surname><given-names>M.</given-names></name>
<name><surname>Taviani</surname><given-names>E.</given-names></name>
<name><surname>Fani</surname><given-names>R.</given-names></name>
<name><surname>Colombo</surname><given-names>M.M.</given-names></name>
<name><surname>Colwell</surname><given-names>R.R.</given-names></name>
<name><surname>Balloux</surname><given-names>F.</given-names></name>
</person-group><article-title>Acquisition and Evolution of SXT-R391 Integrative Conjugative Elements in the Seventh-Pandemic Vibrio Cholerae Lineage</article-title><source>mBio</source><year>2014</year><volume>5</volume><pub-id pub-id-type="doi">10.1128/mBio.01356-14</pub-id><?supplied-pmid 25139901?><pub-id pub-id-type="pmid">25139901</pub-id></element-citation></ref><ref id="B42-jox-11-00013"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sultan</surname><given-names>I.</given-names></name>
<name><surname>Rahman</surname><given-names>S.</given-names></name>
<name><surname>Jan</surname><given-names>A.T.</given-names></name>
<name><surname>Siddiqui</surname><given-names>M.T.</given-names></name>
<name><surname>Mondal</surname><given-names>A.H.</given-names></name>
<name><surname>Haq</surname><given-names>Q.M.R.</given-names></name>
</person-group><article-title>Antibiotics, Resistome and Resistance Mechanisms: A Bacterial Perspective</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><pub-id pub-id-type="doi">10.3389/fmicb.2018.02066</pub-id></element-citation></ref><ref id="B43-jox-11-00013"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kapoor</surname><given-names>G.</given-names></name>
<name><surname>Saigal</surname><given-names>S.</given-names></name>
<name><surname>Elongavan</surname><given-names>A.</given-names></name>
</person-group><article-title>Action and Resistance Mechanisms of Antibiotics: A Guide for Clinicians</article-title><source>J. Anaesthesiol. Clin. Pharmacol.</source><year>2017</year><volume>33</volume><fpage>300</fpage><pub-id pub-id-type="doi">10.4103/joacp.JOACP_349_15</pub-id><pub-id pub-id-type="pmid">29109626</pub-id></element-citation></ref><ref id="B44-jox-11-00013"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reygaert</surname><given-names>W.C.</given-names></name>
</person-group><article-title>An Overview of the Antimicrobial Resistance Mechanisms of Bacteria</article-title><source>AIMS Microbiol.</source><year>2018</year><volume>4</volume><fpage>482</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.3934/microbiol.2018.3.482</pub-id><?supplied-pmid 31294229?><pub-id pub-id-type="pmid">31294229</pub-id></element-citation></ref><ref id="B45-jox-11-00013"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zaman</surname><given-names>S.B.</given-names></name>
<name><surname>Hussain</surname><given-names>M.A.</given-names></name>
<name><surname>Nye</surname><given-names>R.</given-names></name>
<name><surname>Mehta</surname><given-names>V.</given-names></name>
<name><surname>Mamun</surname><given-names>K.T.</given-names></name>
<name><surname>Hossain</surname><given-names>N.</given-names></name>
</person-group><article-title>A Review on Antibiotic Resistance: Alarm Bells Are Ringing</article-title><source>Cureus</source><year>2017</year><volume>9</volume><pub-id pub-id-type="doi">10.7759/cureus.1403</pub-id><?supplied-pmid 28852600?><pub-id pub-id-type="pmid">28852600</pub-id></element-citation></ref><ref id="B46-jox-11-00013"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<name><surname>Cronan</surname><given-names>J.E.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
</person-group><article-title>Triclosan Resistance of Pseudomonas Aeruginosa PAO1 Is due to FabV, a Triclosan-Resistant Enoyl-Acyl Carrier Protein Reductase</article-title><source>Antimicrob. Agents Chemother.</source><year>2010</year><volume>54</volume><fpage>689</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1128/AAC.01152-09</pub-id><pub-id pub-id-type="pmid">19933806</pub-id></element-citation></ref><ref id="B47-jox-11-00013"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Randall</surname><given-names>C.P.</given-names></name>
<name><surname>Mariner</surname><given-names>K.R.</given-names></name>
<name><surname>Chopra</surname><given-names>I.</given-names></name>
<name><surname>O&#x02019;Neill</surname><given-names>A.J.</given-names></name>
</person-group><article-title>The Target of Daptomycin Is Absent from Escherichia Coli and Other Gram-Negative Pathogens</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>57</volume><fpage>637</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1128/AAC.02005-12</pub-id><pub-id pub-id-type="pmid">23114759</pub-id></element-citation></ref><ref id="B48-jox-11-00013"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lebeaux</surname><given-names>D.</given-names></name>
<name><surname>Ghigo</surname><given-names>J.-M.</given-names></name>
<name><surname>Beloin</surname><given-names>C.</given-names></name>
</person-group><article-title>Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2014</year><volume>78</volume><fpage>510</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00013-14</pub-id><pub-id pub-id-type="pmid">25184564</pub-id></element-citation></ref><ref id="B49-jox-11-00013"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Darwich</surname><given-names>L.</given-names></name>
<name><surname>Vidal</surname><given-names>A.</given-names></name>
<name><surname>Seminati</surname><given-names>C.</given-names></name>
<name><surname>Albamonte</surname><given-names>A.</given-names></name>
<name><surname>Casado</surname><given-names>A.</given-names></name>
<name><surname>L&#x000f3;pez</surname><given-names>F.</given-names></name>
<name><surname>Molina-L&#x000f3;pez</surname><given-names>R.A.</given-names></name>
<name><surname>Migura-Garcia</surname><given-names>L.</given-names></name>
</person-group><article-title>High Prevalence and Diversity of Extended-Spectrum &#x003b2;-Lactamase and Emergence of OXA-48 Producing Enterobacterales in Wildlife in Catalonia</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0210686</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0210686</pub-id><pub-id pub-id-type="pmid">31381578</pub-id></element-citation></ref><ref id="B50-jox-11-00013"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alav</surname><given-names>I.</given-names></name>
<name><surname>Sutton</surname><given-names>J.M.</given-names></name>
<name><surname>Rahman</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Role of Bacterial Efflux Pumps in Biofilm Formation</article-title><source>J. Antimicrob. Chemother.</source><year>2018</year><volume>73</volume><fpage>2003</fpage><lpage>2020</lpage><pub-id pub-id-type="doi">10.1093/jac/dky042</pub-id><pub-id pub-id-type="pmid">29506149</pub-id></element-citation></ref><ref id="B51-jox-11-00013"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muktan</surname><given-names>B.</given-names></name>
<name><surname>Thapa Shrestha</surname><given-names>U.</given-names></name>
<name><surname>Dhungel</surname><given-names>B.</given-names></name>
<name><surname>Mishra</surname><given-names>B.C.</given-names></name>
<name><surname>Shrestha</surname><given-names>N.</given-names></name>
<name><surname>Adhikari</surname><given-names>N.</given-names></name>
<name><surname>Banjara</surname><given-names>M.R.</given-names></name>
<name><surname>Adhikari</surname><given-names>B.</given-names></name>
<name><surname>Rijal</surname><given-names>K.R.</given-names></name>
<name><surname>Ghimire</surname><given-names>P.</given-names></name>
</person-group><article-title>Plasmid Mediated Colistin Resistant Mcr-1 and Co-Existence of OXA-48 among Escherichia Coli from Clinical and Poultry Isolates: First Report from Nepal</article-title><source>Gut Pathog.</source><year>2020</year><volume>12</volume><pub-id pub-id-type="doi">10.1186/s13099-020-00382-5</pub-id><?supplied-pmid 32963589?><pub-id pub-id-type="pmid">32963589</pub-id></element-citation></ref><ref id="B52-jox-11-00013"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anyanwu</surname><given-names>M.U.</given-names></name>
<name><surname>Jaja</surname><given-names>I.F.</given-names></name>
<name><surname>Nwobi</surname><given-names>O.C.</given-names></name>
</person-group><article-title>Occurrence and Characteristics of Mobile Colistin Resistance (Mcr) Gene-Containing Isolates from the Environment: A Review</article-title><source>Int. J. Environ. Res. Public Health</source><year>2020</year><volume>17</volume><elocation-id>1028</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph17031028</pub-id></element-citation></ref><ref id="B53-jox-11-00013"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000e1;nchez-Bus&#x000f3;</surname><given-names>L.</given-names></name>
<name><surname>Harris</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Using Genomics to Understand Antimicrobial Resistance and Transmission in Neisseria Gonorrhoeae</article-title><source>Microb. Genom.</source><year>2019</year><volume>5</volume><pub-id pub-id-type="doi">10.1099/mgen.0.000239</pub-id></element-citation></ref><ref id="B54-jox-11-00013"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prasad</surname><given-names>R.</given-names></name>
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Banka</surname><given-names>A.</given-names></name>
</person-group><article-title>Multidrug-Resistant Tuberculosis/Rifampicin-Resistant Tuberculosis: Principles of Management</article-title><source>Lung India</source><year>2018</year><volume>35</volume><fpage>78</fpage><pub-id pub-id-type="doi">10.4103/lungindia.lungindia_98_17</pub-id><pub-id pub-id-type="pmid">29319042</pub-id></element-citation></ref><ref id="B55-jox-11-00013"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verderosa</surname><given-names>A.D.</given-names></name>
<name><surname>Totsika</surname><given-names>M.</given-names></name>
<name><surname>Fairfull-Smith</surname><given-names>K.E.</given-names></name>
</person-group><article-title>Bacterial Biofilm Eradication Agents: A Current Review</article-title><source>Front. Chem.</source><year>2019</year><volume>7</volume><pub-id pub-id-type="doi">10.3389/fchem.2019.00824</pub-id><?supplied-pmid 31850313?><pub-id pub-id-type="pmid">31850313</pub-id></element-citation></ref><ref id="B56-jox-11-00013"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laxminarayan</surname><given-names>R.</given-names></name>
<name><surname>Van Boeckel</surname><given-names>T.</given-names></name>
<name><surname>Frost</surname><given-names>I.</given-names></name>
<name><surname>Kariuki</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>E.A.</given-names></name>
<name><surname>Limmathurotsakul</surname><given-names>D.</given-names></name>
<name><surname>Larsson</surname><given-names>D.G.J.</given-names></name>
<name><surname>Levy-Hara</surname><given-names>G.</given-names></name>
<name><surname>Mendelson</surname><given-names>M.</given-names></name>
<name><surname>Outterson</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>The Lancet Infectious Diseases Commission on Antimicrobial Resistance: 6 Years Later</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>e51</fpage><lpage>e60</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30003-7</pub-id><pub-id pub-id-type="pmid">32059790</pub-id></element-citation></ref><ref id="B57-jox-11-00013"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikaido</surname><given-names>H.</given-names></name>
</person-group><article-title>Multidrug Resistance in Bacteria</article-title><source>Annu. Rev. Biochem.</source><year>2009</year><volume>78</volume><fpage>119</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.78.082907.145923</pub-id><pub-id pub-id-type="pmid">19231985</pub-id></element-citation></ref><ref id="B58-jox-11-00013"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Huseby</surname><given-names>D.L.</given-names></name>
<name><surname>Brandis</surname><given-names>G.</given-names></name>
<name><surname>Hughes</surname><given-names>D.</given-names></name>
</person-group><article-title>Alternative Evolutionary Pathways for Drug-Resistant Small Colony Variant Mutants in Staphylococcus Aureus</article-title><source>mBio</source><year>2017</year><volume>8</volume><pub-id pub-id-type="doi">10.1128/mBio.00358-17</pub-id><?supplied-pmid 28634236?><pub-id pub-id-type="pmid">28634236</pub-id></element-citation></ref><ref id="B59-jox-11-00013"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fern&#x000e1;ndez-Villa</surname><given-names>D.</given-names></name>
<name><surname>Aguilar</surname><given-names>M.R.</given-names></name>
<name><surname>Rojo</surname><given-names>L.</given-names></name>
</person-group><article-title>Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>4996</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20204996</pub-id><?supplied-pmid 31601031?><pub-id pub-id-type="pmid">31601031</pub-id></element-citation></ref><ref id="B60-jox-11-00013"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pang</surname><given-names>Z.</given-names></name>
<name><surname>Raudonis</surname><given-names>R.</given-names></name>
<name><surname>Glick</surname><given-names>B.R.</given-names></name>
<name><surname>Lin</surname><given-names>T.-J.</given-names></name>
<name><surname>Cheng</surname><given-names>Z.</given-names></name>
</person-group><article-title>Antibiotic Resistance in Pseudomonas Aeruginosa: Mechanisms and Alternative Therapeutic Strategies</article-title><source>Biotechnol. Adv.</source><year>2019</year><volume>37</volume><fpage>177</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2018.11.013</pub-id><pub-id pub-id-type="pmid">30500353</pub-id></element-citation></ref><ref id="B61-jox-11-00013"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamed</surname><given-names>S.M.</given-names></name>
<name><surname>Elkhatib</surname><given-names>W.F.</given-names></name>
<name><surname>El-Mahallawy</surname><given-names>H.A.</given-names></name>
<name><surname>Helmy</surname><given-names>M.M.</given-names></name>
<name><surname>Ashour</surname><given-names>M.S.</given-names></name>
<name><surname>Aboshanab</surname><given-names>K.M.A.</given-names></name>
</person-group><article-title>Multiple Mechanisms Contributing to Ciprofloxacin Resistance among Gram Negative Bacteria Causing Infections to Cancer Patients</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><pub-id pub-id-type="doi">10.1038/s41598-018-30756-4</pub-id></element-citation></ref><ref id="B62-jox-11-00013"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandez</surname><given-names>L.</given-names></name>
<name><surname>Hancock</surname><given-names>R.E.W.</given-names></name>
</person-group><article-title>Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance</article-title><source>Clin. Microbiol. Rev.</source><year>2012</year><volume>25</volume><fpage>661</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1128/CMR.00043-12</pub-id><pub-id pub-id-type="pmid">23034325</pub-id></element-citation></ref><ref id="B63-jox-11-00013"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rudolf</surname><given-names>J.D.</given-names></name>
<name><surname>Bigelow</surname><given-names>L.</given-names></name>
<name><surname>Chang</surname><given-names>C.</given-names></name>
<name><surname>Cuff</surname><given-names>M.E.</given-names></name>
<name><surname>Lohman</surname><given-names>J.R.</given-names></name>
<name><surname>Chang</surname><given-names>C.-Y.</given-names></name>
<name><surname>Ma</surname><given-names>M.</given-names></name>
<name><surname>Yang</surname><given-names>D.</given-names></name>
<name><surname>Clancy</surname><given-names>S.</given-names></name>
<name><surname>Babnigg</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Crystal Structure of the Zorbamycin-Binding Protein ZbmA, the Primary Self-Resistance Element in Streptomyces Flavoviridis ATCC21892</article-title><source>Biochemistry</source><year>2015</year><volume>54</volume><fpage>6842</fpage><lpage>6851</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.5b01008</pub-id><pub-id pub-id-type="pmid">26512730</pub-id></element-citation></ref><ref id="B64-jox-11-00013"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sugiyama</surname><given-names>M.</given-names></name>
<name><surname>Kumagai</surname><given-names>T.</given-names></name>
<name><surname>Matsuo</surname><given-names>H.</given-names></name>
<name><surname>Alam Bhuiyan</surname><given-names>Z.</given-names></name>
<name><surname>Ueda</surname><given-names>K.</given-names></name>
<name><surname>Mochizuki</surname><given-names>H.</given-names></name>
<name><surname>Nakamura</surname><given-names>N.</given-names></name>
<name><surname>Davies</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Overproduction of the Bleomycin-Binding Proteins from Bleomycin-Producing Streptomyces Verticillus and a Methicillin-Resistant Staphylococcus Aureus in Escherichia Coli and Their Immunological Characterisation</article-title><source>FEBS Lett.</source><year>1995</year><volume>362</volume><fpage>80</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(95)00218-X</pub-id><pub-id pub-id-type="pmid">7535252</pub-id></element-citation></ref><ref id="B65-jox-11-00013"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dur&#x000e1;n-Manuel</surname><given-names>E.M.</given-names></name>
<name><surname>Cruz-Cruz</surname><given-names>C.</given-names></name>
<name><surname>Ib&#x000e1;&#x000f1;ez-Cervantes</surname><given-names>G.</given-names></name>
<name><surname>Bravata-Alcantar&#x000e1;</surname><given-names>J.C.</given-names></name>
<name><surname>Sosa-Hern&#x000e1;ndez</surname><given-names>O.</given-names></name>
<name><surname>Delgado-Balbuena</surname><given-names>L.</given-names></name>
<name><surname>Le&#x000f3;n-Garc&#x000ed;a</surname><given-names>G.</given-names></name>
<name><surname>Cort&#x000e9;s-Ort&#x000ed;z</surname><given-names>I.A.</given-names></name>
<name><surname>Cure&#x000f1;o-D&#x000ed;az</surname><given-names>M.A.</given-names></name>
<name><surname>Castro-Escarpulli</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Clonal Dispersion of Acinetobacter Baumannii in an Intensive Care Unit Designed to Patients COVID-19</article-title><source>J. Infect. Dev. Ctries.</source><year>2021</year><volume>15</volume><fpage>58</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.3855/jidc.13545</pub-id><?supplied-pmid 33571146?><pub-id pub-id-type="pmid">33571146</pub-id></element-citation></ref><ref id="B66-jox-11-00013"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>Y.X.</given-names></name>
<name><surname>Wang</surname><given-names>C.Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.Y.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wan</surname><given-names>Q.Q.</given-names></name>
<name><surname>Chen</surname><given-names>J.H.</given-names></name>
<name><surname>Tay</surname><given-names>F.R.</given-names></name>
<name><surname>Niu</surname><given-names>L.N.</given-names></name>
</person-group><article-title>Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections</article-title><source>Adv. Sci.</source><year>2019</year><volume>7</volume><fpage>1901872</fpage><pub-id pub-id-type="doi">10.1002/advs.201901872</pub-id></element-citation></ref><ref id="B67-jox-11-00013"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Oliveira</surname><given-names>D.M.P.</given-names></name>
<name><surname>Forde</surname><given-names>B.M.</given-names></name>
<name><surname>Kidd</surname><given-names>T.J.</given-names></name>
<name><surname>Harris</surname><given-names>P.N.A.</given-names></name>
<name><surname>Schembri</surname><given-names>M.A.</given-names></name>
<name><surname>Beatson</surname><given-names>S.A.</given-names></name>
<name><surname>Paterson</surname><given-names>D.L.</given-names></name>
<name><surname>Walker</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Antimicrobial Resistance in ESKAPE Pathogens</article-title><source>Clin. Microbiol. Rev.</source><year>2020</year><volume>33</volume><pub-id pub-id-type="doi">10.1128/CMR.00181-19</pub-id></element-citation></ref><ref id="B68-jox-11-00013"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yam</surname><given-names>E.L.Y.</given-names></name>
<name><surname>Hsu</surname><given-names>L.Y.</given-names></name>
<name><surname>Yap</surname><given-names>E.P.-H.</given-names></name>
<name><surname>Yeo</surname><given-names>T.W.</given-names></name>
<name><surname>Lee</surname><given-names>V.</given-names></name>
<name><surname>Schlundt</surname><given-names>J.</given-names></name>
<name><surname>Lwin</surname><given-names>M.O.</given-names></name>
<name><surname>Limmathurotsakul</surname><given-names>D.</given-names></name>
<name><surname>Jit</surname><given-names>M.</given-names></name>
<name><surname>Dedon</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Antimicrobial Resistance in the Asia Pacific Region: A Meeting Report</article-title><source>Antimicrob. Resist. Infect. Control</source><year>2019</year><volume>8</volume><pub-id pub-id-type="doi">10.1186/s13756-019-0654-8</pub-id></element-citation></ref><ref id="B69-jox-11-00013"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muhammed</surname><given-names>M.T.</given-names></name>
<name><surname>Aki-Yalcin</surname><given-names>E.</given-names></name>
</person-group><article-title>Homology Modeling in Drug Discovery: Overview, Current Applications, and Future Perspectives</article-title><source>Chem. Biol. Drug Des.</source><year>2018</year><volume>93</volume><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1111/cbdd.13388</pub-id><?supplied-pmid 30187647?><pub-id pub-id-type="pmid">30187647</pub-id></element-citation></ref><ref id="B70-jox-11-00013"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iskandar</surname><given-names>K.</given-names></name>
<name><surname>Molinier</surname><given-names>L.</given-names></name>
<name><surname>Hallit</surname><given-names>S.</given-names></name>
<name><surname>Sartelli</surname><given-names>M.</given-names></name>
<name><surname>Hardcastle</surname><given-names>T.C.</given-names></name>
<name><surname>Haque</surname><given-names>M.</given-names></name>
<name><surname>Lugova</surname><given-names>H.</given-names></name>
<name><surname>Dhingra</surname><given-names>S.</given-names></name>
<name><surname>Sharma</surname><given-names>P.</given-names></name>
<name><surname>Islam</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Surveillance of Antimicrobial Resistance in Low- and Middle-Income Countries: A Scattered Picture</article-title><source>Antimicrob. Resist. Infect. Control</source><year>2021</year><volume>10</volume><pub-id pub-id-type="doi">10.1186/s13756-021-00931-w</pub-id></element-citation></ref><ref id="B71-jox-11-00013"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>K&#x000e5;llberg</surname><given-names>C.</given-names></name>
<name><surname>&#x000c5;rdal</surname><given-names>C.</given-names></name>
<name><surname>Salvesen Blix</surname><given-names>H.</given-names></name>
<name><surname>Klein</surname><given-names>E.</given-names></name>
<name><surname>Martinez</surname><given-names>E.M.</given-names></name>
<name><surname>Lindb&#x000e6;k</surname><given-names>M.</given-names></name>
<name><surname>Outterson</surname><given-names>K.</given-names></name>
<name><surname>R&#x000f8;ttingen</surname><given-names>J.-A.</given-names></name>
<name><surname>Laxminarayan</surname><given-names>R.</given-names></name>
</person-group><article-title>Introduction and Geographic Availability of New Antibiotics Approved between 1999 and 2014</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0205166</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0205166</pub-id><pub-id pub-id-type="pmid">30325963</pub-id></element-citation></ref><ref id="B72-jox-11-00013"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rawson</surname><given-names>T.M.</given-names></name>
<name><surname>Moore</surname><given-names>L.S.P.</given-names></name>
<name><surname>Zhu</surname><given-names>N.</given-names></name>
<name><surname>Ranganathan</surname><given-names>N.</given-names></name>
<name><surname>Skolimowska</surname><given-names>K.</given-names></name>
<name><surname>Gilchrist</surname><given-names>M.</given-names></name>
<name><surname>Satta</surname><given-names>G.</given-names></name>
<name><surname>Cooke</surname><given-names>G.</given-names></name>
<name><surname>Holmes</surname><given-names>A.</given-names></name>
</person-group><article-title>Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>71</volume><pub-id pub-id-type="doi">10.1093/cid/ciaa530</pub-id><?supplied-pmid 32358954?><pub-id pub-id-type="pmid">32358954</pub-id></element-citation></ref><ref id="B73-jox-11-00013"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Afshinnekoo</surname><given-names>E.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>C.</given-names></name>
<name><surname>Burguete-Garc&#x000ed;a</surname><given-names>A.</given-names></name>
<name><surname>Castro-Nallar</surname><given-names>E.</given-names></name>
<name><surname>Deng</surname><given-names>Y.</given-names></name>
<name><surname>Desnues</surname><given-names>C.</given-names></name>
<name><surname>Dias-Neto</surname><given-names>E.</given-names></name>
<name><surname>Elhaik</surname><given-names>E.</given-names></name>
<name><surname>Iraola</surname><given-names>G.</given-names></name>
<name><surname>Jang</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 Drug Practices Risk Antimicrobial Resistance Evolution</article-title><source>Lancet Microbe</source><year>2021</year><volume>2</volume><fpage>e135</fpage><lpage>e136</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(21)00039-2</pub-id><pub-id pub-id-type="pmid">33655229</pub-id></element-citation></ref><ref id="B74-jox-11-00013"><label>74.</label><element-citation publication-type="webpage"><article-title>World Health Organization Record Number of Countries Contribute Data Revealing Disturbing Rates of Antimicrobial Resistance. World Health Organization, Geneva</article-title><year>2020</year><comment>Available online: <ext-link xlink:href="https://www.who.int/news-room/detail/01-06-2020-record-number-of-countries-contribute-data-revealing-disturbing-rates-of-antimicrobial-resistance" ext-link-type="uri">https://www.who.int/news-room/detail/01-06-2020-record-number-of-countries-contribute-data-revealing-disturbing-rates-of-antimicrobial-resistance</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-01">(accessed on 1 June 2020)</date-in-citation></element-citation></ref><ref id="B75-jox-11-00013"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Langford</surname><given-names>B.J.</given-names></name>
<name><surname>So</surname><given-names>M.</given-names></name>
<name><surname>Raybardhan</surname><given-names>S.</given-names></name>
<name><surname>Leung</surname><given-names>V.</given-names></name>
<name><surname>Westwood</surname><given-names>D.</given-names></name>
<name><surname>MacFadden</surname><given-names>D.R.</given-names></name>
<name><surname>Soucy</surname><given-names>J.-P.R.</given-names></name>
<name><surname>Daneman</surname><given-names>N.</given-names></name>
</person-group><article-title>Bacterial Co-Infection and Secondary Infection in Patients with COVID-19: A Living Rapid Review and Meta-Analysis</article-title><source>Clin. Microbiol. Infect.</source><year>2020</year><volume>26</volume><pub-id pub-id-type="doi">10.1016/j.cmi.2020.07.016</pub-id></element-citation></ref><ref id="B76-jox-11-00013"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>F.</given-names></name>
<name><surname>Yu</surname><given-names>T.</given-names></name>
<name><surname>Du</surname><given-names>R.</given-names></name>
<name><surname>Fan</surname><given-names>G.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Xiang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>B.</given-names></name>
<name><surname>Gu</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id></element-citation></ref><ref id="B77-jox-11-00013"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lansbury</surname><given-names>L.</given-names></name>
<name><surname>Lim</surname><given-names>B.</given-names></name>
<name><surname>Baskaran</surname><given-names>V.</given-names></name>
<name><surname>Lim</surname><given-names>W.S.</given-names></name>
</person-group><article-title>Co-Infections in People with COVID-19: A Systematic Review and Meta-Analysis</article-title><source>J. Infect.</source><year>2020</year><volume>81</volume><fpage>266</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.05.046</pub-id><pub-id pub-id-type="pmid">32473235</pub-id></element-citation></ref><ref id="B78-jox-11-00013"><label>78.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>Clinical Management of COVID-19</article-title><year>2020</year><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/i/item/clinical-management-of-covid-19" ext-link-type="uri">https://www.who.int/publications/i/item/clinical-management-of-covid-19</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-27">(accessed on 27 May 2020)</date-in-citation></element-citation></ref><ref id="B79-jox-11-00013"><label>79.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>Solidarity Clinical Trial for COVID-19 Treatments</article-title><year>2020</year><comment>Available online: <ext-link xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments" ext-link-type="uri">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-08-11">(accessed on 11 August 2021)</date-in-citation></element-citation></ref><ref id="B80-jox-11-00013"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bork</surname><given-names>J.T.</given-names></name>
<name><surname>Leekha</surname><given-names>S.</given-names></name>
<name><surname>Claeys</surname><given-names>K.</given-names></name>
<name><surname>Seung</surname><given-names>H.</given-names></name>
<name><surname>Tripoli</surname><given-names>M.</given-names></name>
<name><surname>Amoroso</surname><given-names>A.</given-names></name>
<name><surname>Heil</surname><given-names>E.L.</given-names></name>
</person-group><article-title>Change in Hospital Antibiotic Use and Acquisition of Multidrug-Resistant Gram-Negative Organisms after the Onset of Coronavirus Disease 2019</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2020</year><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1017/ice.2020.1360</pub-id></element-citation></ref><ref id="B81-jox-11-00013"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knight</surname><given-names>G.M.</given-names></name>
<name><surname>Glover</surname><given-names>R.E.</given-names></name>
<name><surname>McQuaid</surname><given-names>C.F.</given-names></name>
<name><surname>Olaru</surname><given-names>I.D.</given-names></name>
<name><surname>Gallandat</surname><given-names>K.</given-names></name>
<name><surname>Leclerc</surname><given-names>Q.J.</given-names></name>
<name><surname>Fuller</surname><given-names>N.M.</given-names></name>
<name><surname>Willcocks</surname><given-names>S.J.</given-names></name>
<name><surname>Hasan</surname><given-names>R.</given-names></name>
<name><surname>van Kleef</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Antimicrobial Resistance and COVID-19: Intersections and Implications</article-title><source>eLife</source><year>2021</year><volume>10</volume><fpage>e64139</fpage><pub-id pub-id-type="doi">10.7554/eLife.64139</pub-id><pub-id pub-id-type="pmid">33588991</pub-id></element-citation></ref><ref id="B82-jox-11-00013"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huttner</surname><given-names>B.D.</given-names></name>
<name><surname>Catho</surname><given-names>G.</given-names></name>
<name><surname>Pano-Pardo</surname><given-names>J.R.</given-names></name>
<name><surname>Pulcini</surname><given-names>C.</given-names></name>
<name><surname>Schouten</surname><given-names>J.</given-names></name>
</person-group><article-title>COVID-19: Don&#x02019;t Neglect Antimicrobial Stewardship Principles!</article-title><source>Clin. Microbiol. Infect.</source><year>2020</year><volume>26</volume><fpage>808</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.04.024</pub-id><pub-id pub-id-type="pmid">32360446</pub-id></element-citation></ref><ref id="B83-jox-11-00013"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cave</surname><given-names>E.</given-names></name>
</person-group><article-title>COVID-19 Super-Spreaders: Definitional Quandaries and Implications</article-title><source>Asian Bioeth. Rev.</source><year>2020</year><volume>12</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1007/s41649-020-00118-2</pub-id><?supplied-pmid 32427202?><pub-id pub-id-type="pmid">32427202</pub-id></element-citation></ref><ref id="B84-jox-11-00013"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tacconelli</surname><given-names>E.</given-names></name>
<name><surname>Carrara</surname><given-names>E.</given-names></name>
<name><surname>Savoldi</surname><given-names>A.</given-names></name>
<name><surname>Harbarth</surname><given-names>S.</given-names></name>
<name><surname>Mendelson</surname><given-names>M.</given-names></name>
<name><surname>Monnet</surname><given-names>D.L.</given-names></name>
<name><surname>Pulcini</surname><given-names>C.</given-names></name>
<name><surname>Kahlmeter</surname><given-names>G.</given-names></name>
<name><surname>Kluytmans</surname><given-names>J.</given-names></name>
<name><surname>Carmeli</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis</article-title><source>Lancet Infect. Dis.</source><year>2018</year><volume>18</volume><fpage>318</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30753-3</pub-id><pub-id pub-id-type="pmid">29276051</pub-id></element-citation></ref><ref id="B85-jox-11-00013"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheesman</surname><given-names>M.J.</given-names></name>
<name><surname>Ilanko</surname><given-names>A.</given-names></name>
<name><surname>Blonk</surname><given-names>B.</given-names></name>
<name><surname>Cock</surname><given-names>I.E.</given-names></name>
</person-group><article-title>Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution?</article-title><source>Pharmacogn. Rev.</source><year>2017</year><volume>11</volume><fpage>57</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.4103/phrev.phrev_21_17</pub-id><pub-id pub-id-type="pmid">28989242</pub-id></element-citation></ref><ref id="B86-jox-11-00013"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khameneh</surname><given-names>B.</given-names></name>
<name><surname>Iranshahy</surname><given-names>M.</given-names></name>
<name><surname>Soheili</surname><given-names>V.</given-names></name>
<name><surname>Fazly Bazzaz</surname><given-names>B.S.</given-names></name>
</person-group><article-title>Review on Plant Antimicrobials: A Mechanistic Viewpoint</article-title><source>Antimicrob. Resist. Infect. Control</source><year>2019</year><volume>8</volume><pub-id pub-id-type="doi">10.1186/s13756-019-0559-6</pub-id></element-citation></ref><ref id="B87-jox-11-00013"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taneja</surname><given-names>N.</given-names></name>
<name><surname>Sharma</surname><given-names>M.</given-names></name>
</person-group><article-title>Antimicrobial Resistance in the Environment: The Indian Scenario</article-title><source>Indian J. Med. Res.</source><year>2019</year><volume>149</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.4103/ijmr.IJMR_331_18</pub-id><?supplied-pmid 31219076?><pub-id pub-id-type="pmid">31219076</pub-id></element-citation></ref><ref id="B88-jox-11-00013"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nwaiwu</surname><given-names>O.</given-names></name>
<name><surname>Aduba</surname><given-names>C.C.</given-names></name>
</person-group><article-title>An in silico analysis of acquired antimicrobial resistance genes in <italic toggle="yes">Aeromonas</italic> plasmids</article-title><source>AIMS Microbiol.</source><year>2020</year><volume>6</volume><fpage>75</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.3934/microbiol.2020005</pub-id><?supplied-pmid 32226916?><pub-id pub-id-type="pmid">32226916</pub-id></element-citation></ref><ref id="B89-jox-11-00013"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Panja</surname><given-names>A.S.</given-names></name>
<name><surname>Sarkar</surname><given-names>A.</given-names></name>
<name><surname>Biswas</surname><given-names>R.</given-names></name>
<name><surname>Bandyopadhyay</surname><given-names>B.</given-names></name>
<name><surname>Bandopadhyay</surname><given-names>R.</given-names></name>
</person-group><article-title>Modification of Drug-Binding Proteins Associated with the Efflux Pump in MDR-MTB in Course of Evolution: An Unraveled Clue Based on in Silico Approach</article-title><source>J. Antibiot.</source><year>2019</year><volume>72</volume><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1038/s41429-019-0146-3</pub-id><?supplied-pmid 30799437?><pub-id pub-id-type="pmid">30799437</pub-id></element-citation></ref><ref id="B90-jox-11-00013"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feldgarden</surname><given-names>M.</given-names></name>
<name><surname>Brover</surname><given-names>V.</given-names></name>
<name><surname>Gonzalez-Escalona</surname><given-names>N.</given-names></name>
<name><surname>Frye</surname><given-names>J.G.</given-names></name>
<name><surname>Haendiges</surname><given-names>J.</given-names></name>
<name><surname>Haft</surname><given-names>D.H.</given-names></name>
<name><surname>Hoffmann</surname><given-names>M.</given-names></name>
<name><surname>Pettengill</surname><given-names>J.B.</given-names></name>
<name><surname>Prasad</surname><given-names>A.B.</given-names></name>
<name><surname>Tillman</surname><given-names>G.E.</given-names></name>
<etal/>
</person-group><article-title>AMRFinderPlus and the Reference Gene Catalog Facilitate Examination of the Genomic Links among Antimicrobial Resistance, Stress Response, and Virulence</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><pub-id pub-id-type="doi">10.1038/s41598-021-91456-0</pub-id></element-citation></ref><ref id="B91-jox-11-00013"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodrigues</surname><given-names>G.L.</given-names></name>
<name><surname>Panzenhagen</surname><given-names>P.</given-names></name>
<name><surname>Ferrari</surname><given-names>R.G.</given-names></name>
<name><surname>dos Santos</surname><given-names>A.</given-names></name>
<name><surname>Paschoalin</surname><given-names>V.M.F.</given-names></name>
<name><surname>Conte-Junior</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Frequency of Antimicrobial Resistance Genes in Salmonella from Brazil by in Silico Whole-Genome Sequencing Analysis: An Overview of the Last Four Decades</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><pub-id pub-id-type="doi">10.3389/fmicb.2020.01864</pub-id><?supplied-pmid 32849452?><pub-id pub-id-type="pmid">32849452</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jox-11-00013-f001"><label>Figure 1</label><caption><p>Schematic representation of various factors, causes and consequences contributing towards the emergence and spread of antimicrobial resistance.</p></caption><graphic xlink:href="jox-11-00013-g001" position="float"/></fig><fig position="float" id="jox-11-00013-f002"><label>Figure 2</label><caption><p>Diagrammatic illustration of few possible mechanisms in bacteria contributing towards various antibiotic resistance such as: 1. Active efflux of various antibiotic via pumps; 2. Prevention or decrease drug uptake by the cell; 3. Antibiotic inactivating enzymes; 4. Modification or alteration of targets; 5. Use of alternative or bypass metabolic pathways; 6. Acquired antibiotic resistance mechanism (HGT).</p></caption><graphic xlink:href="jox-11-00013-g002" position="float"/></fig><table-wrap position="float" id="jox-11-00013-t001"><object-id pub-id-type="pii">jox-11-00013-t001_Table 1</object-id><label>Table 1</label><caption><p>Different mode of action of antibiotics and its resistance mechanisms along-with few bacterial examples.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mode of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Resistance</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Examples</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x000df;-Lactams<break/>(Cephalosporin, Carbapenems, etc.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptidoglycan biosynthesis<break/>Cell wall synthesis Inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydrolysis, efflux, altered target, reduced permeability, inactivation of antibiotics via &#x000df;-lactamase (extended spectrum &#x000df;-lactamase; carbapenem-hydrolyzing &#x000df;-lactamase)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus aureus, Pseudomonas aeruginosa</italic>, Enteric bacteria, <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Vibrio cholerae, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>,<xref rid="B30-jox-11-00013" ref-type="bibr">30</xref>,<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>,<xref rid="B43-jox-11-00013" ref-type="bibr">43</xref>,<xref rid="B44-jox-11-00013" ref-type="bibr">44</xref>,<xref rid="B45-jox-11-00013" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aminoglycosides<break/>(Gentamicin, Streptomycin, Spectinomycin, Amikacin, Tobramycin, etc.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of Translation and cell membrane synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modifying enzyme inactivation by Phosphorylation (phosphorylase), acetylation (acetylase), nucleotidylation, efflux, altered target ribosomal binding site, decrease uptake by reducing permeability, other modifying enzymes includes acetyltransferases, adenyl transferases, phosphotransferases.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enteric bacteria, Staphylococci, Streptococci, Bacteriodes,<break/><italic toggle="yes">Pseudomonas aeruginosa</italic>, <italic toggle="yes">Vibrio cholerae, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, etc.</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>,<xref rid="B30-jox-11-00013" ref-type="bibr">30</xref>,<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>,<xref rid="B43-jox-11-00013" ref-type="bibr">43</xref>,<xref rid="B44-jox-11-00013" ref-type="bibr">44</xref>,<xref rid="B45-jox-11-00013" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycopeptides<break/>(Vancomycin, Teicoplanin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptidoglycan biosynthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Altered target</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enterococci, Lactobacilli, <italic toggle="yes">Staphylococcus haemolyticus</italic>,<break/><italic toggle="yes">Enterococcus</italic><break/><italic toggle="yes">faecium,</italic>
<italic toggle="yes">Enterococcus</italic><break/><italic toggle="yes">faecalis, etc.</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-jox-11-00013" ref-type="bibr">30</xref>,<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>,<xref rid="B43-jox-11-00013" ref-type="bibr">43</xref>,<xref rid="B44-jox-11-00013" ref-type="bibr">44</xref>,<xref rid="B45-jox-11-00013" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetracyclines<break/>(Tigecycline, Minocycline, Doxycycline)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30S ribosomal subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monooxygenation, ABC efflux pump, ribosomal modification, tetracycline inactivating enzyme</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Staphylococci, Streptococci, Enterococci, Enterobacteriaceae, Haemophilus, Listeria, <italic toggle="yes">Acinetobacter baumannii,</italic> etc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-jox-11-00013" ref-type="bibr">30</xref>,<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>,<xref rid="B43-jox-11-00013" ref-type="bibr">43</xref>,<xref rid="B44-jox-11-00013" ref-type="bibr">44</xref>,<xref rid="B45-jox-11-00013" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Macrolides<break/>(Erythromycin, azithromycin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Translation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycosylation, efflux, methylation of rRNA target</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Streptococci, Enterococci, Staphylococci,<break/><italic toggle="yes">Acinetobacter baumannii</italic>, etc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>,<xref rid="B43-jox-11-00013" ref-type="bibr">43</xref>,<xref rid="B45-jox-11-00013" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phenicols<break/>(Chloramphenicol, Azidamphenicol, Thiamphenicol) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Translation inhibitors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acetylation by chloramphenicol acetyltransferase, efflux pump, target site alteration</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bacillus subtilis, Streptococcus pneumoniae</italic>, Enterobacteriaceae, <italic toggle="yes">Haemophilus influenzae</italic>, <italic toggle="yes">Vibrio cholerae, Escherichia coli</italic> etc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>,<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>,<xref rid="B43-jox-11-00013" ref-type="bibr">43</xref>,<xref rid="B44-jox-11-00013" ref-type="bibr">44</xref>,<xref rid="B45-jox-11-00013" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Folate inhibitors<break/>(Trimethoprim, Sulfamethoxazole) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit folate synthesis pathways</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Efflux, altered target</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Staphylococci, Streptococci, Enterobacteriaceae, Neisseria, <italic toggle="yes">Acinetobacter baumannii</italic>, etc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-jox-11-00013" ref-type="bibr">30</xref>,<xref rid="B45-jox-11-00013" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycins<break/>(Rifampin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transcription</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ADP-ribosylation, efflux, altered DNA-dependent RNA target </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enteric bacteria, Staphylococci, Streptococci, <italic toggle="yes">Mycobacterium tuberculosis</italic>,<break/><italic toggle="yes">Vibrio cholerae, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii</italic>, etc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>,<xref rid="B30-jox-11-00013" ref-type="bibr">30</xref>,<xref rid="B45-jox-11-00013" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quinolone<break/>(nalidixic acid, ciprofloxacin, levofloxacin, ofloxacin, norfloxacin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibitors of DNA synthesis<break/>Topoisomerase I and II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Altered DNA gyrase or DNA topoisomerase IV subunit A (parC) efflux or reduced permeability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermis</italic>, <italic toggle="yes">Streptococcus pneumoniae</italic><break/><italic toggle="yes">Acinetobacter baumannii</italic><break/>etc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B12-jox-11-00013" ref-type="bibr">12</xref>,<xref rid="B30-jox-11-00013" ref-type="bibr">30</xref>,<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>,<xref rid="B43-jox-11-00013" ref-type="bibr">43</xref>,<xref rid="B44-jox-11-00013" ref-type="bibr">44</xref>,<xref rid="B45-jox-11-00013" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cationic peptides (Colistin, Polymyxin-B)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell membrane<break/>Lipopolysaccahride layer of bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Altered target, efflux</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Escherichia coli, Salmonella Typhimurium</italic>,<break/><italic toggle="yes">Acinetobacter baumannii</italic>, etc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-jox-11-00013" ref-type="bibr">30</xref>,<xref rid="B42-jox-11-00013" ref-type="bibr">42</xref>,<xref rid="B45-jox-11-00013" ref-type="bibr">45</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>